WO2021043227A1 - 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 - Google Patents

用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 Download PDF

Info

Publication number
WO2021043227A1
WO2021043227A1 PCT/CN2020/113341 CN2020113341W WO2021043227A1 WO 2021043227 A1 WO2021043227 A1 WO 2021043227A1 CN 2020113341 W CN2020113341 W CN 2020113341W WO 2021043227 A1 WO2021043227 A1 WO 2021043227A1
Authority
WO
WIPO (PCT)
Prior art keywords
taste
salt
masking
vortioxetine hydrobromide
vortioxetine
Prior art date
Application number
PCT/CN2020/113341
Other languages
English (en)
French (fr)
Inventor
贾强
黄法
王如
杨金金
魏友兵
马天华
王云中
胡彦云
褚长虎
Original Assignee
普济生物科技（台州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74736746&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2021043227(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020227004281A priority Critical patent/KR20220061952A/ko
Priority to JP2022502045A priority patent/JP2022540249A/ja
Priority to BR112022002122A priority patent/BR112022002122A2/pt
Priority to MX2022002444A priority patent/MX2022002444A/es
Priority to EP20861501.3A priority patent/EP4026539A4/en
Application filed by 普济生物科技（台州）有限公司 filed Critical 普济生物科技（台州）有限公司
Priority to CA3146024A priority patent/CA3146024A1/en
Priority to US17/617,805 priority patent/US20220249466A1/en
Priority to AU2020343816A priority patent/AU2020343816A1/en
Publication of WO2021043227A1 publication Critical patent/WO2021043227A1/zh
Priority to ZA2022/00542A priority patent/ZA202200542B/en
Priority to JP2023063529A priority patent/JP2023089096A/ja
Priority to JP2023180274A priority patent/JP2024010032A/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • This application relates to the technical field of pharmaceutical preparations, in particular to coated particles, solid dispersions, compositions and preparations for oral taste masking.
  • Vortioxetine (also known as vothiaxetine) is a multi-target antidepressant with both 5-HT 3 receptor antagonism and 5-HT 1A receptor agonism. It is used for the treatment of major depression. At present, the hydrobromide of vortioxetine is used clinically as its active ingredient. It was jointly developed by Takeda and Lundbeck. It was approved by the FDA on September 30, 2013. The trade name is Brintellix has four approved specifications, 5mg, 10mg, 15mg and 20mg, and the dosage form is film-coated tablets.
  • Vortioxetine hydrobromide 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide
  • the English name is Vortioxetine hydrobromide
  • the molecular formula is C 18 H 22 N 2 S ⁇ HBr.
  • US9562024B2 discloses the hydrobromic acid half-salt compound of vortioxetine, that is, every two vortioxetine molecules share one hydrobromic acid molecule, and the molecular formula is C 18 H 22 N 2 S ⁇ 1/2HBr.
  • the structural formulas of C 18 H 22 N 2 S ⁇ HBr and C 18 H 22 N 2 S ⁇ 1/2HBr are as follows:
  • Depression is a common disease, with strong clinical demand. However, during the onset of depression, patients often refuse or do not cooperate with treatment, and spit out the pills they take when the medical staff and home nursing staff are not paying attention. Ordinary tablets and capsules are "integral tablets”. Mental patients, the elderly, and long-term bedridden patients (the tablets are stuck in the esophagus) are still dangerous to take. Therefore, there is a clinical need for more suitable dosage forms to improve patients' medication compliance or compliance.
  • Oral dispersible formulations enable the drug to exist in the oral cavity in the state of particulate preparations (such as granules, powders, suspensions, dry suspensions) or liquid formulations (such as oral suspensions), or in the oral cavity quickly Change to a particulate state or a liquid state (for example, orally disintegrating tablets, orally dispersible tablets).
  • Oral dispersible dosage form is the most suitable technical means to improve the compliance of patients with depression.
  • orally disintegrating tablet is the best dosage form because of its convenient use, convenient carrying, convenient transportation, and stable quality.
  • the first method is to reduce the solubility of the drug and reduce the exposure of the drug in the oral cavity.
  • Another method is to change the ability of the drug to interact with taste receptors, which will affect the taste-related receptors, which will have potentially unknown side effects. Therefore, the first method is safer for patients.
  • In order to reduce the irritation of the drug in the oral cavity it is necessary to reduce the exposure of the drug in the oral cavity and reduce the dissolution of the drug; however, while reducing the dissolution of the drug, it will also slow down the absorption of the drug, thereby affecting the absorption and absorption of the immediate-release dosage form.
  • the rate of metabolism affects the efficacy and safety of the drug.
  • flavoring agents to correct taste is also a method to adjust the unfavorable taste of raw materials such as bitterness and astringency, but the effect of flavoring agents on improving the irritation of vortioxetine is very poor.
  • one or more embodiments of the present application provide a taste-masked immediate-release formulation of vortioxetine, which adopts suitable excipients and The preparation method improves patient compliance and compliance.
  • the orally dispersible preparations of the present application are tablets, granules, capsules, powders, suspensions, dry suspensions, and solutions.
  • the tablet is an orally disintegrating tablet or a dispersible tablet.
  • One or more embodiments of the present application provide an oral dispersible taste masking formulation of vortioxetine hydrobromide half or mono salt, which comprises vortioxetine hydrobromide half or mono salt and a pharmaceutically acceptable mask. Flavor accessories.
  • the vortioxetine hydrobromide half-salt or mono-salt is coated with the taste-masking excipient to form coated granules .
  • the taste-masking excipients in the coated particles are cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, methacrylic acid copolymer, Chitosan, copovidone, or polyvinyl alcohol.
  • the taste-masking adjuvant in the coated granule includes an alkaline adjuvant.
  • the coated particles include an anti-sticking agent.
  • the half-salt or mono-salt of vortioxetine hydrobromide in the oral-dispersible taste-masking preparation is dispersed in the taste-masking adjuvant to form a solid dispersion.
  • the taste-masking adjuvant in the solid dispersion is cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, methacrylic acid copolymer, chitosan Sugars, copovidone, povidone, polyvinyl alcohol, or polyethylene glycols.
  • the taste-masking adjuvant in the solid dispersion includes an alkaline adjuvant.
  • the half salt or one salt of vortioxetine hydrobromide in the solid dispersion is mixed with an alkaline adjuvant.
  • the half or mono salt of vortioxetine hydrobromide in the solid dispersion is combined with trisodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, potassium carbonate, and carbonic acid.
  • trisodium phosphate disodium hydrogen phosphate
  • dipotassium hydrogen phosphate potassium carbonate
  • carbonic acid e.g., sodium, sodium bicarbonate, potassium citrate, sodium acetate, calcium hydroxide, sodium hydroxide, potassium hydroxide, or meglumine is mixed to form a composition.
  • One or more embodiments of the present application provide taste-masking coated granules of vortioxetine hydrobromide hemi-salt or mono-salt, wherein the taste-masking coating excipients of the taste-masking coated granules are cellulose acetate, Ethyl cellulose, hydroxypropyl cellulose, methacrylic acid copolymer, chitosan, copovidone, or polyvinyl alcohol.
  • the taste-masking coating adjuvant includes an alkaline adjuvant.
  • the taste-masking coating adjuvant includes an anti-sticking agent.
  • One or more embodiments of the present application provide a taste-masking solid dispersion of vortioxetine hydrobromide half salt or mono-salt, wherein the taste-masking excipients are cellulose acetate, ethyl cellulose, and hydroxypropyl fiber Vegetables, methacrylic acid copolymers, chitosan, copovidone, povidone, polyvinyl alcohol, or polyethylene glycol.
  • the taste-masking adjuvant includes an alkaline adjuvant.
  • One or more embodiments of the present application provide a taste-masking composition of vortioxetine hydrobromide half or monosalt, which comprises vortioxetine hydrobromide half or monosalt and an alkaline adjuvant.
  • the alkaline adjuvant in the taste-masking composition is trisodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, potassium carbonate, sodium carbonate, sodium bicarbonate, and citric acid. At least one of potassium acid, sodium acetate, calcium hydroxide, sodium hydroxide, potassium hydroxide, or meglumine.
  • the methacrylic copolymer in the orally dispersed taste-masking formulation, taste-masked coated particles, or taste-masked solid dispersion is a polyacrylic resin.
  • the polyacrylic resin in the oral-dispersed taste-masking formulation, taste-masked coated particles, or taste-masked solid dispersion is polyacrylic resin II or polyacrylic resin IV.
  • vortioxetine hydrobromide half-salt or mono-salt in the orodispersible taste-masking preparation or taste-masking coated granules is coated with taste-masking excipients to form coated granules, so The coated particles are further dispersed in the taste-masking auxiliary material to form a solid dispersion; in addition, the formed solid dispersion can be further mixed with an alkaline auxiliary material.
  • the vortioxetine hydrobromide half-salt or mono-salt in the oral-dispersed taste-masking preparation or solid dispersion is dispersed in the taste-masking adjuvant to form a solid dispersion, so The solid dispersion is further coated with taste-masking excipients to form coated granules; in addition, the formed coated granules can be further mixed with alkaline excipients.
  • vortioxetine hydrobromide half-salt or mono-salt in the orodispersible taste-masking preparation or taste-masking coated granules is coated with taste-masking excipients to form coated granules, so The coated granules are further mixed with alkaline auxiliary materials.
  • the vortioxetine hydrobromide half-salt or mono-salt in the oral-dispersed taste-masking preparation or solid dispersion is dispersed in the taste-masking adjuvant to form a solid dispersion, so The solid dispersion is further mixed with alkaline auxiliary materials.
  • the taste-masking coating excipients in the oral-dispersed taste-masking preparation or taste-masking coating granules are cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, and cellulose acetate. Based acrylic copolymers, chitosan, copovidone, or polyvinyl alcohol.
  • the taste-masking excipients in the oral-dispersed taste-masking preparation or taste-masking solid dispersion are cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, and methacrylic acid. Copolymers, chitosan, copovidone, povidone, polyvinyl alcohol, or polyethylene glycol.
  • the alkaline adjuvant in the oral dispersible taste-masking preparation or taste-masking composition is trisodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, potassium carbonate, sodium carbonate, and hydrogen carbonate. At least one of sodium, potassium citrate, sodium acetate, calcium hydroxide, sodium hydroxide, potassium hydroxide, or meglumine.
  • the oral dispersion of taste-masking preparations, taste-masked coated granules, taste-masked solid dispersions, or taste-masked composition of vortioxetine hydrobromide half salt or mono-salt is combined with
  • the weight ratio of pharmaceutically acceptable taste-masking excipients used to form coatings or solid dispersions is 1:0.1-1:5, such as 1:0.3-1:3, 1:0.5-1:1.5, and another example is 1: 0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4 or 1:5.
  • the weight ratio of vortioxetine hydrobromide half or monosalt to the pharmaceutically acceptable alkaline excipient is 1:0.01-1:1.1, for example, 1:0.01-1: 1, another example is 1:0.01, 1:0.02, 1:0.03, 1:0.04, 1:0.05, 1:0.06, 1:0.07, 1:0.08, 1:0.09, 1:0.1, 1:0.5, 1: 1. 1:1.1.
  • the oral dispersible taste-masking formulation, taste-masked coated particles, taste-masked solid dispersion, or taste-masked composition of the present application is a crystalline or amorphous substance.
  • the oral dispersible taste-masking formulation, taste-masked coated granules, taste-masked solid dispersion, or taste-masked composition of the present application further comprises a filler, a flavoring agent, and a release modifier , Plasticizer, anti-sticking agent and/or disintegrant.
  • the anti-sticking agent is talc, which accounts for 5%-25% of the total weight of the taste-masking coated particles, such as 10%-20%, and for example 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%.
  • the flavoring agent is neotame, which accounts for 0.05%-0.5%, for example, 0.1%, 0.2%, or 0.3% of the total weight of the oral dispersible taste-masking preparation.
  • the release modifier is polyethylene glycol or an alkaline adjuvant.
  • the disintegrant is sodium starch glycolate, croscarmellose sodium, crospovidone, and combinations thereof, which account for the total weight of the oral dispersible taste-masking preparation 1%-8%, preferably 2%-6%.
  • the oral dispersion of taste-masked formulations, taste-masked coated granules, taste-masked solid dispersions, or taste-masked compositions is or is prepared as a tablet, granule, capsule, or powder , Suspension, dry suspension, solution.
  • the tablet is an orally disintegrating tablet or a dispersible tablet.
  • the orodispersible formulation, the orodispersible taste-masked formulation, the taste-masked coated granules, the taste-masked solid dispersion, or the vortioxetine hydrobromide half salt in the taste-masked composition Or a salt is amorphous or crystal.
  • the oral dispersion or oral dispersion taste-masking preparation is a tablet, granule, capsule, powder, suspension, dry suspension, or solution.
  • the tablet is an orally disintegrating tablet or a dispersible tablet.
  • One or more embodiments of the present application provide the use of vortioxetine hydrobromide monosalt in the preparation of oral dispersions, taste-masked coated granules, taste-masked solid dispersions, taste-masked compositions, or orally dispersed taste-masked formulations the use of.
  • the preparation of the oral dispersion or the oral dispersion and taste masking preparation is a tablet, granule, capsule, powder, suspension, dry suspension, or solution.
  • the tablet is an orally disintegrating tablet or a dispersible tablet.
  • One or more embodiments of the present application provide a method for preparing taste-masked coated granules of vortioxetine hydrobromide hemi-salt or mono-salt or a preparation thereof, which comprises:
  • (2a) Disperse the taste-masking adjuvant in a solvent, coat the vortioxetine hydrobromide half-salt or mono-salt powder with the taste-masking adjuvant through a fluidized bed and remove the solvent to obtain the taste-masking adjuvant coating Vortioxetine hydrobromide half salt or one salt; or (2b) adding the vortioxetine hydrobromide half salt or one salt powder and taste-masking excipients to a solvent to form vortioxetine hydrobromide half salt Or a salt suspension, after removing the solvent by fluidized bed, spray drying or evaporation, the taste-masking excipient-coated vortioxetine hydrobromide half salt or mono salt is obtained;
  • the coated vortioxetine hydrobromide half salt or mono salt is prepared as a preparation.
  • a 20-300 mesh sieve such as a 100, 150, or 200 mesh sieve.
  • the taste-masking adjuvant and the release modifier are dispersed in a solvent.
  • the release modifier is polyethylene glycol or an alkaline adjuvant.
  • the solvent is water, ethanol or dichloromethane;
  • the vortioxetine hydrobromide half or mono-salt powder, taste-masking excipients, release regulators and plasticizers are added to a solvent to form a suspension of vortioxetine hydrobromide half or mono-salt;
  • the plasticizer is polyethylene glycol or triethyl citrate;
  • the solvent is water, ethanol or dichloromethane.
  • One or more embodiments of the present application provide a method for preparing a solid dispersion of vortioxetine hydrobromide hemi-salt or mono-salt or a preparation thereof, which comprises:
  • step (2a) or (2b) is prepared as a formulation.
  • after crushing it is passed through a 20-300 mesh sieve, for example, through a 100, 150 or 200 mesh sieve.
  • the vortioxetine hydrobromide hemi-salt or mono-salt powder, taste-masking excipients and release modifiers are mixed.
  • the solvent is water, ethanol or dichloromethane.
  • the taste-masking adjuvant is cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, methacrylic acid copolymer, chitosan, copolyvinyl cellulose Ketones, povidone, polyvinyl alcohol, or polyethylene glycols.
  • the methacrylic acid copolymer is a polyacrylic resin.
  • the polyacrylic resin is polyacrylic resin II or polyacrylic resin IV.
  • One or more embodiments of the present application provide a method for preparing a taste-masking composition of vortioxetine hydrobromide hemi-salt or mono-salt or a preparation thereof, which comprises:
  • the taste-masking composition is prepared as a formulation.
  • a 50-300 mesh sieve Preferably, after crushing, it is passed through a 50-300 mesh sieve, more preferably a 100-200 mesh sieve;
  • the alkaline auxiliary material is trisodium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium citrate, sodium acetate, calcium hydroxide, sodium hydroxide, hydrogen Potassium oxide, or meglumine;
  • the powder can be prepared into a conventional formulation using conventional methods in the art.
  • the weight ratio of vortioxetine hydrobromide half or monosalt to the pharmaceutically acceptable taste-masking excipient is 1:0.1-1:5, such as 1:0.5-1 :1.5, 1:0.3-1:1.5, 1:0.3-1:1.3, another example is 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1 :0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, or 1:5; weight of vortioxetine hydrobromide half or one salt and pharmaceutically acceptable alkaline excipients
  • the ratio is 1:0.01-1:1.1, preferably 1:0.01-1:1.
  • One or more embodiments of the present application provide a solid dispersion comprising vortioxetine hydrobromide half salt and polyacrylic resin IV, wherein the weight of the vortioxetine hydrobromide half salt and polyacrylic resin IV The ratio is 1:0.1-1:5, such as 1:0.3-1:2, 1:0.5-1:1.5, or 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1 :0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, or 1:5.
  • One or more embodiments of the present application provide a solid dispersion formed by vortioxetine hydrobromide mono-salt and polyacrylic acid resin IV, wherein the weight of the vortioxetine hydrobromide half-salt and polyacrylic resin IV
  • the ratio is 1:0.1-1:5, 1:0.3-1:2, 1:0.5-1:1.5, for example 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1: 0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, or 1:5.
  • the solid dispersion containing vortioxetine hydrobromide half salt and polyacrylic resin IV has the characteristic peak shown in FIG. 20.
  • the solid dispersion formed by vortioxetine hydrobromide monosalt and polyacrylic resin IV has the characteristic peak shown in FIG. 22.
  • the X-ray powder diffraction pattern expressed in 2 ⁇ angles has characteristic peaks at the following positions: 4.2 ⁇ 0.2°, 14.5 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.2 ⁇ 0.2°, and 22.6 ⁇ 0.2°.
  • the X-ray powder diffraction pattern expressed in 2 ⁇ angles has characteristic peaks at the following positions: 4.2 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.6 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.2 ⁇ 0.2°, 21.5 ⁇ 0.2°, 22.6 ⁇ 0.2°, 24.4 ⁇ 0.2°, 26.0 ⁇ 0.2°, 28.2 ⁇ 0.2°, and 29.0 ⁇ 0.2°.
  • a solid dispersion comprising vortioxetine hydrobromide half salt and polyacrylic resin IV, or a solid formed of vortioxetine hydrobromide mono salt and polyacrylic resin IV
  • the dispersion also includes at least one of PEG 4000, PEG 6000, and PEG 8000.
  • the weight ratio of the polyacrylic resin IV to at least one of PEG 4000, PEG 6000, and PEG 8000 is 1:0.05-1:2, such as 1:0.05, 1 :0.1, 1:0.5, 1:1, 1:1.5, or 1:2.
  • One or more embodiments of the present application provide the oral dispersible taste-masking preparation, taste-masked coated granules, taste-masked solid dispersion, and taste-masked composition of vortioxetine hydrobromide hemi-salt or mono-salt of the present application. Use in the preparation of antidepressant drugs.
  • One or more embodiments of the present application provide the oral dispersible taste-masking preparations, taste-masked coated particles, taste-masked solid dispersions, and taste-masked compositions of vortioxetine hydrobromide hemi-salt or mono-salt of the present application, It is used to treat depression or prepare antidepressant drugs.
  • One or more embodiments of the present application provide a method for treating depression, the method comprising administering the vortioxetine hydrobromide half-salt or mono-salt of vortioxetine hydrobromide according to any one of the preceding claims to a subject in need thereof Oral dispersible taste-masking preparations, taste-masked coated granules, taste-masked solid dispersions, taste-masked compositions.
  • the orally dispersible preparation enables the drug to be in the oral cavity in the form of a particulate preparation (e.g., granule, powder, suspension, dry suspension) or a liquid preparation (e.g., oral suspension). It exists in a liquid state, or can be quickly transformed into a particulate state or a liquid state in the oral cavity (for example, orally disintegrating tablets, orally dispersible tablets).
  • a particulate preparation e.g., granule, powder, suspension, dry suspension
  • a liquid preparation e.g., oral suspension
  • vortioxetine hydrobromide powder is embedded or coated with suitable taste-masking polymer excipients to obtain coated granules, which are then prepared according to the well-known oral preparation preparation method Orally dispersible formulations.
  • the oral dispersible formulation of vortioxetine hydrobromide comprises vortioxetine hydrobromide, one of a taste-masking polymer, chitosan, and deacetyl chitosan
  • the vortioxetine hydrobromide orally dispersible formulation further contains an anti-sticking agent to prevent sticking during the preparation of the taste-masked coated particles, and the proportion (accounting for the taste-masked particles) The total weight) is 5%-25%.
  • the anti-sticking agent may be talc.
  • the vortioxetine hydrobromide orally dispersible preparation further contains a flavoring agent, the proportion of which (accounting for the total weight of the preparation) is 0.05%-0.5%.
  • the flavoring agent may be Neotame.
  • One or more embodiments of the present application provide a second solution.
  • Vortioxetine hydrobromide and suitable polymer adjuvants are made into a crystalline or amorphous solid dispersion, and then the method for preparing a well-known oral preparation Make an oral dispersion preparation.
  • the vortioxetine hydrobromide orally dispersible taste-masking preparation further contains a flavoring agent, and the proportion (the ratio of the total weight of the preparation) of the vortioxetine hydrobromide is 0.05%-0.5%.
  • the flavoring agent may be Neotame.
  • the third solution provided by one or more embodiments of the present application uses weakly alkaline excipients to temporarily change the pH environment where the drug is dispersed in the oral cavity, causing the oral cavity to dissolve below the stimulation threshold and return to acidic in the gastric juice.
  • the pH environment also solves the problems of oral exposure and dissolution and absorption metabolism in the gastrointestinal tract.
  • the vortioxetine hydrobromide orally dispersible taste masking preparation comprises vortioxetine hydrobromide, an alkaline or weakly alkaline taste masking agent and a flavoring agent.
  • the taste masking agent in the oral dispersible taste masking preparation of vortioxetine hydrobromide is a medicinal alkaline excipient, including but not limited to trisodium phosphate and disodium hydrogen phosphate , Dipotassium hydrogen phosphate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium citrate, sodium acetate, calcium hydroxide, sodium hydroxide, potassium hydroxide, or meglumine.
  • the flavoring agent in the vortioxetine hydrobromide oral dispersible taste-masking preparation is a flavoring agent that can be used for medicine, including but not limited to Neotame.
  • the taste-masked coated particles or taste-masked solid dispersion of vortioxetine hydrobromide can be prepared as an oral preparation of vortioxetine hydrobromide for oral dispersion.
  • the oral exposure or dispersion formulations of taste-masked coated particles of vortioxetine hydrobromide or taste-masked solid dispersions include, but are not limited to, formulations that can be in the oral cavity in particulate form (such as granules, powders, suspensions, dry suspensions) or solution formulations (such as oral solutions), or can quickly transform into a particulate or solution state (such as orally disintegrating tablets, orally dispersible tablets) in the oral cavity. sheet). .
  • (2a) Disperse the taste-masking excipients in a solvent, coat the vortioxetine hydrobromide powder with the taste-masking excipients through a fluidized bed and remove the solvent to obtain the taste-masking excipients-coated hydrobromide Tioxetine; preferably, the taste-masking adjuvant and the release regulator are dispersed in a solvent; more preferably, the release regulator is polyethylene glycol or an alkaline adjuvant; preferably, the solvent is water, ethanol or Methylene chloride; or
  • the vortioxetine hydrobromide powder and taste-masking excipients are added to the solvent to form a suspension, and the solvent is removed by fluidized bed, spray drying or evaporation to obtain the taste-masking excipient-coated vortioxetine hydrobromide
  • the vortioxetine hydrobromide powder, taste-masking excipients, and/or release regulators and plasticizers are added to a solvent to form a suspension of vortioxetine hydrobromide;
  • the The plasticizer is polyethylene glycol or triethyl citrate; preferably, the solvent is water, ethanol or dichloromethane;
  • the coated vortioxetine hydrobromide is prepared as a formulation.
  • (2a) Mix the vortioxetine hydrobromide powder and taste-masking excipients, heat at 50-150°C to soften or liquefy, cool to solidify, and crush to obtain a powder; preferably, the vortioxetine hydrobromide Xetine powder, taste-masking excipients and release modifiers are mixed; or
  • step (2a) or (2b) is prepared as a formulation.
  • the vortioxetine hydrobromide half salt or monosalt powder with alkaline adjuvants to obtain a taste-masking composition; preferably, the alkaline adjuvants are trisodium phosphate, disodium hydrogen phosphate, and sodium carbonate , Sodium bicarbonate, tripotassium citrate, sodium acetate, calcium hydroxide, or meglumine;
  • the taste-masking composition is prepared as a formulation.
  • a half salt or a salt of vortioxetine hydrobromide can be used, and an amorphous or crystalline half salt or a salt of vortioxetine hydrobromide can be used. salt.
  • the release modifier in the above preparation method includes but is not limited to mannitol, sorbitol, xylitol, polyethylene glycol, hydroxypropyl cellulose, and/or hypromellose Cellulose.
  • the plasticizer in the above preparation method includes but is not limited to polyethylene glycol and/or triethyl citrate.
  • the preparation method of vortioxetine hydrobromide oral dispersion and taste-masking preparation adopts one or more pharmaceutically acceptable resins and vortioxetine hydrobromide to co-dissolve One or more pharmaceutically acceptable solvents to obtain a true solution.
  • the microcrystalline hydrobromide vortex is obtained in the confined space of the polymer Oxetine solid dispersion; according to the conventional preparation process, adding other well-known excipients in a prescribed amount, and then using a small molecule alkaline material to mask the taste, the oral exposure type vortioxetine hydrobromide oral dispersion and taste masking preparation can also be prepared.
  • polyacrylic acid resin IV and vortioxetine hydrobromide mono or half salt are dissolved in a solvent, and vortioxetine hydrobromide mono or half salt is dissolved in a solvent.
  • the weight ratio of resin IV is 1:0.1-1:5, preferably 1:0.3-1:2, more preferably 1:0.5-1:1.5. After removing the solvent, a solid dispersion is obtained.
  • the characteristic peaks of powder crystal diffraction are: 4.2 ⁇ 0.2°, 14.5 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.2 ⁇ 0.2°, and 22.6 ⁇ 0.2°; furthermore, the characteristic peaks of powder crystal diffraction are: 4.2 ⁇ 0.2°, 14.5 ⁇ 0.2°, 16.6 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.2 ⁇ 0.2°, 21.5 ⁇ 0.2°, 22.6 ⁇ 0.2°, 24.4 ⁇ 0.2°, 26.0 ⁇ 0.2°, 28.2 ⁇ 0.2°, And 29.0 ⁇ 0.2°.
  • the solid dispersion has been proved to be stable in dissolution, stable in impurities and stable in crystalline state through stability studies.
  • the preparation method of vortioxetine oral dispersible taste-masking formulation adopts one or more pharmaceutically acceptable resins and vortioxetine hydrobromide to be co-dissolved in pharmaceutically acceptable One or more solvents, and then reduce the solubility of the solution or remove the solvent, vortioxetine and the resin form a solid dispersion and its particles; according to the conventional preparation process, adding other well-known excipients in a prescribed amount, hydrobromic acid can be prepared Vortioxetine oral dispersible taste-masking preparation; wherein Vortioxetine exists in the resin in an ionic or molecular state, and interacts with the functional groups in the resin, so that the dissociation in the oral environment is slowed down, and after passing through the environment of gastric juice , Can quickly dissociate into vortioxetine in the gastrointestinal tract.
  • one or more pharmaceutically acceptable resins and vortioxetine hydrobromide half or one salt are used to co-dissolve in one or more pharmaceutically acceptable solvents, Then reduce the solubility of the solution (for example, add a poor solvent, or lower the temperature) or remove the solvent to obtain an amorphous solid dispersion of vortioxetine hydrobromide; according to the conventional preparation process, add other well-known excipients in the prescription amount, Alkaline excipients can be optionally added to the external excipients to mix. Alkaline excipients can change the microenvironment of receptors on mucous membranes and taste buds and reduce irritation. Among them, vortioxetine hydrobromide exists in an amorphous aggregation state.
  • the resin includes, but is not limited to, polyacrylic resins (L, S type or type II, type III, type IV), containing functional groups -NH 2 , NR 2 , -COOH,- COO -, -SO 3 H, or -SO 3 - methacrylic resins, divinylbenzene resin and a polystyrene type resin is a linear polymer material.
  • polyacrylic resins L, S type or type II, type III, type IV
  • divinylbenzene resin and a polystyrene type resin is a linear polymer material.
  • the preparation method of vortioxetine hydrobromide orally dispersible taste-masking formulation combines one or more pharmaceutically acceptable taste-masking excipients and one or more pharmaceutically acceptable
  • the solid dispersion is prepared by hot-melt granulation and hot-melt extrusion processes, and other well-known excipients are added in the prescribed amount according to the conventional preparation process; solid dispersion It can be mixed with alkaline taste-masking adjuvants, or can be further coated with taste-masking adjuvants.
  • the vortioxetine hydrobromide oral dispersible taste-masking preparation releases slowly or not in the oral environment, and after passing through the environment of gastric juice, it can quickly dissociate into vortioxetine hydrobromide in the gastrointestinal tract, and is Road absorption.
  • the basic linear polymer material includes, but is not limited to, polyacrylic resins (such as type II or type IV), chitosan, or amino sugar polymers.
  • the release modifier includes, but is not limited to, mannitol, sorbitol, sugar alcohol, polyethylene glycol, hydroxypropyl cellulose, or hypromellose.
  • vortioxetine half salt has lower oral and tongue irritation, it can be prepared into a solid dispersion with polymer excipients, which greatly improves the dissolution rate and total dissolution rate of vortioxetine in the gastrointestinal tract, while maintaining No oral irritation.
  • Disintegration speed is an important clinical indicator of orally disintegrating tablets. Pharmacopoeias in various countries recommend no more than 1 minute. The faster the better in clinical practice, especially for drugs with patient compliance problems. Freeze-dried orally disintegrating tablets can adopt freeze-drying technology. The active ingredients of the drug are uniformly dispersed in the matrix material solution in a micronized or solution state, and the finished product after quantitative packaging and freeze-drying can be disintegrated within 5 seconds; but the process Complex and difficult to industrialize. Compressed orally disintegrating tablets use general tablet preparation technology.
  • the disintegration time limit of 1 minute can also be reached; but reducing the tablet pressure will greatly affect The strength of the tablet is a lot of inconvenience due to wear and tear during production, transportation and use.
  • researchers use a variety of disintegrants to obtain a composite disintegrant that can ensure the normal strength of the finished product in the tablet. Within the range, control the disintegration within 10 seconds.
  • the composite disintegrant includes but is not limited to sodium starch glycolate, croscarmellose sodium, and crospovidone.
  • the weight ratio of sodium starch glycolate, croscarmellose sodium and crospovidone is 1:1:1, and the weight ratio in the formulation is 1% respectively. -8%, for example 2%-6%.
  • this application uses polymers that are recognized as safe.
  • the currently known molding products of this type of polymer mainly include polyacrylic resin type II and polyacrylic acid resin type IV (Utraki E type), among which Eudragit E is the English trade name Eudragit E, and the common name is Amino Methacrylate Copolymer. It is included in the USP40-NF35 edition of the United States Pharmacopoeia. The FDA has determined that the maximum daily dosage of the polymer is 214.28mg when used in orally disintegrating tablets for taste masking, which can meet the needs of vortioxetine hydrobromide for taste masking, especially its analogues. E100 has the same chemical structure, physical and chemical properties and quality standards, and can also meet the needs of preparation.
  • the flavor is further improved by selectively adding a flavoring agent to correct the flavor, while providing a variety of flavor options.
  • a flavoring agent used in this technology is Neotame, which has been included in the USP40-NF35 edition of the United States Pharmacopoeia. Neotame has been widely used as a food additive.
  • an alkaline adjuvant taste masking agent can significantly reduce its irritation to the tongue, and the irritation can be reduced to a clinically acceptable level.
  • the taste masking agent used is a pharmaceutically acceptable excipient.
  • the formulation provided by one or more embodiments of the present application can improve patient compliance and compliance, improve the dissolution of vortioxetine hydrobromide, potentially improve the bioavailability of the drug, and solve the problem of vortioxetine in the prior art.
  • the oral preparation of Ting has a single dosage form and does not adapt to the shortcomings of clinical differentiation and individualized administration needs.
  • the inventor of the present application conducted research on commercially available vortioxetine hydrobromide film-coated tablets: single use of 20mg, 10mg and 5mg specifications, after oral dispersion, there is obvious bitterness and long-term strong delayed irritation. . Oral irritation limits the development and clinical application of other oral preparations except film-coated tablets.
  • Figure 1 X-ray powder diffraction pattern of vortioxetine hydrobromide half salt.
  • Figure 2 X-ray powder diffraction pattern of vortioxetine hydrobromide mono salt ( ⁇ form).
  • Figure 3 X-ray powder diffraction pattern of vortioxetine hydrobromide mono salt ( ⁇ -type).
  • Figure 8 UV scan of vortioxetine hydrobromide salt in 0.1N hydrochloric acid.
  • Figure 9 UV scan of Eudragit EPO in 0.1N hydrochloric acid.
  • Figure 12 UV scan of vortioxetine hydrobromide half salt in 0.1N hydrochloric acid.
  • Figure 17 UV scan of polyacrylic acid resin IV in 0.1N hydrochloric acid.
  • Figure 20 X-ray powder diffraction pattern of solid dispersion of vortioxetine hydrobromide half salt-polyacrylic resin IV.
  • Figure 21 X-ray powder diffraction pattern of polyacrylic resin IV after spray drying.
  • Figure 22 X-ray powder diffraction pattern of solid dispersion of vortioxetine hydrobromide monosalt-polyacrylic acid resin IV.
  • Figure 24 X-ray powder diffraction pattern of polyacrylic resin II (rotary evaporation of ethanol).
  • the European Pharmacopoeia is named Methyl methacrylate-methacrylic acid copolymer (1:1)
  • the US Pharmacopoeia is named Methacrylic Acid Copolymer Type A
  • the Chinese Pharmacopoeia is named polyacrylic resin II.
  • it can be purchased from Supplier Roma Company (for example, the product name is Youteqi L, Youteqi L100, Youteqi L PO) or Anhui Shanhe Pharmaceutical Excipients Co., Ltd. (for example, the product name is Polyacrylic Resin II).
  • polyacrylic resin IV in this article its U.S. Pharmacopoeia is named Amino Methacrylate Copolymer
  • Chinese Pharmacopoeia is named polyacrylic resin IV.
  • it can be purchased from the supplier Rohm (for example, the trade name Youtech E100, You Teqi E PO), Guangzhou Maofeng Pharmaceutical Excipients Co., Ltd. (for example, the trade name is Youshi E, Youshi E100) or Anhui Shanhe Pharmaceutical Excipients Co., Ltd. (for example, the product name is polyacrylic acid resin IV).
  • polyacrylic resins For other polyacrylic resins, they can be purchased from, for example, Rohm Company, for example, under the trade names Youditch RL100, Youditch L100, Youditch RS PO, and Youditch S100.
  • the excipients used in the examples are not related to this patent. When using this patent to prepare formulations, other well-known common and functional pharmaceutical excipients can be used according to the dosage form, stability of the formulation and the needs of clinical use.
  • vortioxetine hydrobromide monosalt does not indicate the specific crystal form used, which means that the crystal form ⁇ , ⁇ or ⁇ can be used.
  • the instrument used for X-ray powder diffraction (XRD) is D/max-2200/pc, equipped with theta-2 ⁇ goniometer RINT2000 Vertical goniometer, MO monochromator, and Scintillation counter detector.
  • the acquisition software is XG operation.
  • the instrument is calibrated with the single crystal silicon standard that comes with the instrument.
  • the detection conditions are: the 2 ⁇ scanning angle range is 3-40° or 3-50°, the step length is 0.02°, and the speed is 6°/min.
  • Detection process using copper target K ⁇ X-rays with a wavelength of 1.54nm, under the operating conditions of 40kV and 20mA, the samples are tested at room temperature, and the required samples are placed on the Si P non-reflective board. The sample is sieved before testing.
  • UV-2600 type UV-2600 type, Shimadzu, Japan.
  • Rotary evaporator R205, Taizhou Xinli Electronic Equipment Co., Ltd.
  • Hot air circulation oven DHG-9070A, Shanghai Yiheng Scientific Instrument Co., Ltd.
  • Vortex mixer Vortex-2 Shanghai Huxi Industrial Co., Ltd.
  • Multifunctional fluidized bed BWF-1G, Chongqing Yingge Granulation Coating Technology Co., Ltd.
  • Vacuum freeze dryer FD-2D, Beijing Boyikang Experimental Instrument Co., Ltd.
  • High-efficiency coating machine Labcoating IV, Shenzhen Xinyite Technology Co., Ltd.
  • Dry granulator GL-5B, Zhejiang Tomorrow Machinery Co., Ltd.
  • Granulator P100, Shenzhen Xinyite Technology Co., Ltd.
  • Portable pH meter STARTER 300 type.
  • Freeze dryer SCIENT2-30F, Ningbo Xinzhi Biological Technology Co., Ltd.
  • PH and exposure (calculated as vortioxetine) detection method take a piece of this product (or a powder equivalent to 20 mg of vortioxetine), add 5.0 grams of purified water, and incubate at 36 ⁇ 2°C after airtight shaking and dispersing.
  • V S The volume of 0.1mol/mL silver nitrate titrant consumed by the sample, mL
  • V b volume consumed by blank, mL
  • N equivalent concentration of silver nitrate titrant
  • the taste masking effect was evaluated by the subject's perception of the bitterness and irritation of the oral cavity and tongue of the test sample.
  • Example 1 of patent US9562024B2 to prepare vortioxetine hydrobromide half salt. Specifically: Take 8.00g (26.8mmol) of vortioxetine in a 250mL round-bottomed flask, add 122mL of ethanol and dissolve it ultrasonically; take 2.70g of hydrobromic acid (concentration of 40% by weight, 13.3mmol), add 16mL Ethanol is ultrasonically dissolved; under stirring conditions, slowly drop the ethanol solution of hydrobromic acid into the ethanol solution of vortioxetine.
  • Example 4a of Patent Document WO2007/144005A1 was used to synthesize the ⁇ crystal form of vortioxetine monosalt. Specifically: Dissolve 2.0g 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in 30mL of hot ethyl acetate, and add 0.73mL 48%-wt hydrogen Bromic acid aqueous solution. The reaction solution formed a thick liquid. In order to be suitable for stirring, 10 mL of ethyl acetate was added, and the obtained liquid was stirred at room temperature for 1 hour. The feed liquid was filtered and dried under vacuum (20°C) overnight to produce 2.0 g of white solid product with a yield of 80%. The product is the ⁇ crystal form product of vortioxetine hydrobromide mono-salt. The bromine content measured by the titration method was 20.76%.
  • the vortioxetine mono-salt ⁇ crystal form was synthesized by referring to the preparation method of Example 4c of Patent Document WO2007/144005A1. Specifically: 49.5g 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine was dissolved in 500mL ethyl acetate, and 18.5mL 48%-wt hydrobromic acid was added Aqueous solution. The reaction solution formed a thick liquid, which was stirred overnight at room temperature. It was filtered and dried under vacuum (50°C) overnight to produce 29.6 g of white solid product with a yield of 47%. The product is the ⁇ crystal form product of vortioxetine hydrobromide mono salt. The bromine content measured by the titration method was 20.69%.
  • the vortioxetine mono-salt ⁇ crystal form was synthesized with reference to the preparation method of Example 4e of Patent Document WO2007/144005A1. Specifically: 1g of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide was dissolved in 20mL of water and heated to 85°C. The reaction solution was basically clear, and 1 was added dropwise. Drop the HBr aqueous solution to make it clear. Aqueous HBr solution was added until a cloud point was observed. The solution was cooled to room temperature, filtered and dried. The product is the ⁇ crystal form of vortioxetine hydrobromide mono-salt. The bromine content measured by the titration method is 20.73%.
  • a taste-masked powder equivalent to 20mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100-mesh powder of vortioxetine hydrobromide half salt equivalent to 20mg of vortioxetine, it was proved that the irritation Improved.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • E100:PEG6000 1:0.23 X-ray powder diffraction pattern after spray drying As shown in Figure 4.
  • a taste-masked powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the vortioxetine hydrobromide mono-salt ⁇ type 100 mesh powder equivalent to 20 mg of vortioxetine.
  • the stimulus has improved.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • a taste-masked powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the vortioxetine hydrobromide mono-salt ⁇ type 100 mesh powder equivalent to 20 mg of vortioxetine.
  • the stimulus has improved.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • a taste-masked powder equivalent to 20mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100-mesh powder of vortioxetine hydrobromide half salt equivalent to 20mg of vortioxetine, it was proved that there was irritation. Improved.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • a taste-masked powder equivalent to 20mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100-mesh powder of vortioxetine hydrobromide half salt equivalent to 20mg of vortioxetine, it was proved that there was irritation. Improved.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension
  • For materials observe the state of materials at any time. After spraying, stop heating after 30 minutes. After the temperature of the materials drops to room temperature, collect the materials, sieving to collect powder with a particle size of less than 80 meshes, and obtain 7.81 grams of taste-masked powder, with a yield of 43.98 %, the detected powder content is 48.63% (based on vortioxetine).
  • the taste-masking powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and the taste masked powder was taken with the equivalent of 20 mg of vortioxetine half salt of vortioxetine hydrobromide 100 Compared with the powder, it proves that the irritation is improved more.
  • Homemade sample 1 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Homemade sample 2 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension Observe the state of the material at any time. After spraying is finished, stop heating after 30 minutes. After the material temperature drops to room temperature, collect the material, sieving to collect the powder with a particle size of less than 80 mesh, and obtain 6.98 grams of taste-masked powder with a yield of 39.44 %, the detected powder content is 44.63% (based on vortioxetine).
  • the remaining material was lightly ground and then sieved to collect powder with a particle size of less than 80 meshes to obtain 5.93 grams of taste-masked powder, the yield was 33.50%, and the detected powder content was 45.38% (calculated as vortioxetine).
  • the taste-masking powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and the taste masked powder was taken with the equivalent of 20 mg of vortioxetine half salt of vortioxetine hydrobromide 100 Compared with the powder, it proves that the irritation is improved more.
  • Homemade sample 1 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Homemade sample 2 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension Observe the material status at any time. After spraying, stop heating after 30 minutes. After the material temperature drops to room temperature, collect the material and sieve to collect the powder with a particle size of less than 80 meshes. The taste-masked powder is 6.97 grams, and the yield is 40.76. %, the detected powder content is 47.93% (based on vortioxetine).
  • the remaining materials were lightly ground and then sieved to collect powder with a particle size of less than 80 meshes.
  • the taste-masked powder was 6.00 g, the yield was 33.90% (calculated as vortioxetine), and the powder content detected was 48.98% (calculated as vortioxetine). ).
  • the taste-masking powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and the taste masked powder was taken with the equivalent of 20 mg of vortioxetine hydrobromide half salt 100 Compared with the powder, it proves that the irritation is improved more.
  • Homemade sample 1 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Homemade sample 2 Instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Control substance instantaneous stimulation++, disappeared after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 30-33m 3 , the inlet air temperature 60-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray the prepared Suspend the material and observe the material status at any time. After spraying, stop heating after 30 minutes. After the material temperature drops to room temperature, collect the material. After light grinding, sieve and collect the powder with a particle size of less than 80 meshes to obtain a taste-masking powder 12.79 G, the yield was 75.24%, and the detected powder content was 50.99% (calculated as vortioxetine).
  • a taste-masked powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100 mesh powder of vortioxetine hydrobromic acid half salt equivalent to 20 mg of vortioxetine, it was proved that the irritation was improved. More.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension Observe the material status at any time. After spraying is finished, stop heating after 30 minutes. After the material temperature drops to room temperature, collect the material, lightly grind and sieve to collect the powder with a particle size of less than 80 mesh, and get the taste-masking powder 13.78g, get The rate was 66.54%, and the detected content was 41.79% (calculated as vortioxetine).
  • a taste-masked powder equivalent to 20mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100-mesh powder of vortioxetine hydrobromide half salt equivalent to 20mg of vortioxetine, it was proved that the irritation was improved. It is very large and almost non-irritating.
  • Control substance instantaneous stimulation++, disappeared after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension Observe the material status at any time. After spraying, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, lightly grind and sieve to collect the powder with a particle size of less than 80 mesh, to obtain 14.14 grams of taste-masked powder. The rate was 68.31%, and the detected content was 42.01% (based on vortioxetine).
  • a taste-masked powder equivalent to 20mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100-mesh powder of vortioxetine hydrobromide half salt equivalent to 20mg of vortioxetine, it was proved that the irritation was improved. Very large, almost non-irritating.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • copovidone AV64 Take 10.00 g of copovidone AV64, add it to 70.00 g of medicinal ethanol, stir and dissolve it for later use.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, and spray into the prepared suspension Observe the material status at any time. After spraying, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, lightly grind and sieve to collect the powder with a particle size of less than 80 mesh, and get the taste-masking powder 14.16g. The rate is 70.80%, and the detected content is 42.78% (calculated as vortioxetine).
  • a taste-masked powder equivalent to 20 mg of vortioxetine was taken, and the taste was tested by 5 subjects, and compared with the 100 mesh powder of vortioxetine hydrobromic acid half salt equivalent to 20 mg of vortioxetine, it was proved that the irritation was improved. Very large, almost non-irritating.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • Vortex-2 vortex mixer Take 5.00 g of vortioxetine hydrobromide monosalt and 2.50 g of Eudragit RS PO that have passed through a 200-mesh stainless steel sieve, put them in a clean and dry 50ml screw-top glass reagent bottle, and mix it with a Vortex-2 vortex mixer. After passing through a 100 mesh stainless steel sieve, continue to mix with a vortex mixer for 5 minutes. Take out 0.50 g of the sample for testing. The remaining materials are collected and stacked in a stainless steel tray with a diameter of 75 mm. Placed in a DHG-9070A hot-air circulating oven, 120-130°C After heating for 30 minutes, the material becomes a semi-fluid state. After taking it out and letting it cool, it is pulverized through a 100-mesh stainless steel sieve with a BJ-300A multifunctional pulverizer to obtain a 1:0.5 mixture powder.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Vortex-2 type vortex Mix with a mixer for 5 minutes. After passing through a 100-mesh stainless steel sieve, continue to mix with a vortex mixer for 5 minutes. Take out 0.50 g of the sample for testing. The remaining materials are collected and piled up in a stainless steel tray with a diameter of 75 mm, and placed in a DHG-9070A hot air circulation oven.
  • the material After heating at 120-130°C for 30 minutes, the material becomes semi-fluid. After taking it out and letting it cool, it is pulverized through a 100-mesh stainless steel sieve with a BJ-300A multifunctional pulverizer to obtain 10.98 grams of 1:1.5 mixture powder. The yield was 87.84%, and the content detection was 35.71% (calculated as vortioxetine).
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume 33m 3 , the inlet air temperature 50-55°C, the material feed temperature 50-55°C, the peristaltic pump speed 8rpm, and the atomization pressure 1.0-1.5 Atm, spray into the above steps to prepare the solution, observe the state of the material at any time, and adjust the parameters appropriately to ensure normal atomization and drying. After the spray is completed, stop heating after 30 minutes.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the solid dispersion in 9a) has been tested for stability according to the requirements of the 2015 edition of the Pharmacopoeia of the People’s Republic of China (accelerated for 6 months, 40 ⁇ 2°C, humidity 75% ⁇ 5%), and the stability is good; the solid dispersion in 9a)
  • the dissolution rate of the body in 0.1N hydrochloric acid and pH 4.5 acetate buffer (paddle method, 50 rpm) is fast (10 minutes data) and complete (30 minutes). The results are shown in Table 23.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • the obtained material is 11.73 grams, the yield is 66.27%, the detected content is 44.47% (calculated as vortioxetine), and the measured bromine content of vortioxetine hydrobromide in the solid dispersion is 11.83%.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the solid dispersion in 9b) has been tested for stability according to the requirements of the 2015 edition of the Pharmacopoeia of the People’s Republic of China (accelerated for 6 months, 40 ⁇ 2°0, humidity 75% ⁇ 5%), and the stability is good; the solid in 9b)
  • the dissolution rate of the dispersion in 0.1N hydrochloric acid and pH 4.5 acetate buffer (paddle method, 50 rpm) is fast (10 minutes data) and complete (30 minutes). The results are shown in Table 25.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , Get 17.17 grams of material, the yield is 66.81%, and the detected content is 30.57% (calculated as vortioxetine).
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes.
  • the obtained material is 49.29 grams, the yield is 82.15%, and the detected content is 14.67% (calculated as vortioxetine).
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 80 mesh , That is.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Control substance instantaneous stimulation +++, disappear after 30 minutes of delayed stimulation, unacceptable bitterness.
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Example 1d Take 10.00 grams of the powder of Example 1d and add it to the above solution. After stirring and dispersing, pass through a 60-mesh stainless steel screen, and continue to stir to prevent sedimentation.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 50-55°C, the speed of the peristaltic pump 8rpm, and the atomization pressure of 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is over, stop heating after 30 minutes.
  • the powder is 15.87 g, the yield is 79.35%, and the content is 25.47% (calculated as vortioxetine).
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Example 9a Take 10.00 g of the powder of Example 9a and add it to the above solution. After stirring and dispersing, pass through a 60-mesh stainless steel screen, and continue to stir to prevent settling.
  • the BWF-1G multifunctional fluidized bed installed according to the top spray granulation mode, set the air volume to 33m 3 , the inlet temperature of 60-65°C, the peristaltic pump speed 8rpm, the atomization pressure 1.0-1.5atm, spray into the above steps to prepare the solution , Observe the state of the material at any time, and adjust the parameters appropriately to ensure that the atomization and drying are normal. After the spraying is completed, stop heating after 30 minutes. After the temperature of the material drops to room temperature, collect the material, grind and sieve to collect the powder with a particle size of less than 60 mesh , Get 11.11 grams of powder, yield 74.07%, content 35.17% (calculated as vortioxetine).
  • Control substance instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, and the bitterness is unacceptable.
  • Example 9b Take the powder prepared in Example 9b, microcrystalline cellulose, mannitol P100SD, sodium starch glycolate, and magnesium stearate in a clean and dry 50ml screw-top glass reagent bottle, and mix with a vortex mixer After five minutes, take out the 80-mesh sieve and continue mixing for five minutes. After taking out the 80-mesh sieve and continue mixing for five minutes, the compressed premix is obtained;
  • the tablet core is coated with a high-efficiency coating machine, and the actual weight gain of the tablet core is about 1%.
  • the finished product of this application has undergone preliminary stability tests in accordance with the requirements of the 2015 edition of the Pharmacopoeia of the People’s Republic of China, and compared with the commercially available products.
  • the finished product of this application is tested in 0.1N hydrochloric acid and pH 4.5 acetate buffer.
  • the dissolution rate (paddle method, 50 rpm) is significantly faster than the commercial product, and the dissolution rate (30 minutes) is significantly better than the commercial product.
  • the results are shown in Table 43.
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 100 mesh sieve for use;
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 100 mesh sieve for use;
  • Self-made sample 19a instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Self-made sample 19b instantaneous stimulation++, it disappears after 30 minutes of delayed stimulation, the bitterness is unacceptable.
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 100 mesh sieve for use;
  • the sample dissolved in the oral cavity within 10 seconds, there was no grit, almost no irritation, and the taste was good.
  • Purified water is added to 16 grams to make 40 tablets, each of which is about 0.4 grams, and contains about 0.1548 grams of solids.
  • Vortioxetine hydrobromide hydrogen half salt and red iron oxide are passed through a 100-mesh sieve for use;
  • freeze-dried sample is heat-sealed to obtain a freeze-dried orally disintegrating tablet.
  • the sample After testing by 10 volunteer subjects, the sample disintegrated within 5 seconds in the oral cavity, with no grit feeling and minimal irritation.
  • Subject Transient stimulation Delayed stimulation (minutes) Bitterness Grit Subject 1 + 1-15 Acceptable no Subject 2 + 1-15 Acceptable no Subject 3 ++ 1-15 Acceptable no Subject 4 + 1-15 Acceptable no Subject 5 + 1-15 Acceptable no Subject 6 + 1-15 Acceptable no Subject 7 + 1-15 Acceptable no Subject 8 ++ 1-15 Acceptable no Subject 9 + 1-15 Acceptable no Subject 10 + 1-15 Acceptable no
  • Vortioxetine hydrobromide half salt micronized powder coating powder is made into 100 tablets, each weighing 0.152 grams, and the formula is as follows:
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 80 mesh sieve for use;
  • Example 3a (2) Weigh the powder prepared in Example 3a, sodium bicarbonate, mannitol P100SD, crospovidone XL, croscarmellose sodium, sodium starch glycolate, magnesium stearate, sodium carboxymethyl cellulose, sodium bicarbonate, mannitol P100SD, crospovidone XL, croscarmellose sodium, sodium starch glycolate, magnesium stearate, and sodium carboxymethyl cellulose prepared in Example 3a.
  • Purified water is added to 16 grams to make 40 tablets, each about 0.4 grams, containing about 0.1799 grams of solids
  • the raw material medicine is ready after passing through a 100-mesh sieve
  • freeze-dried sample is heat-sealed to obtain a freeze-dried orally disintegrating tablet.
  • the pH and relative exposure test values are:
  • the sample 22a disintegrated in the oral cavity within 10 seconds
  • the sample 20b disintegrated in the oral cavity within 5 seconds, and there was no grit feeling and minimal irritation.
  • Self-made sample 22a instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Self-made sample 22b instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 80 mesh sieve for use;
  • Example 7a (2) Weigh the powder prepared in Example 7a of the prescription amount, anhydrous tripotassium phosphate, mannitol P100SD, crospovidone XL, croscarmellose sodium, sodium starch glycolate, magnesium stearate, Put neotame, red iron oxide and other materials in a 50ml glass preparation bottle, tighten the cap, mix with a vortex mixer for five minutes, then take out an 80 mesh stainless steel sieve, mix with a vortex mixer for five minutes, then take out an 80 mesh stainless steel sieve Then, mix with a vortex mixer for five minutes to obtain a tablet premix;
  • Purified water is added to 16 grams to make 40 tablets, each about 0.4 grams, containing about 0.1881 grams of solids
  • the raw material medicine is ready after passing through a 100-mesh sieve
  • freeze-dried sample is heat-sealed to obtain a freeze-dried orally disintegrating tablet.
  • the pH and relative exposure test values are:
  • the sample 21a disintegrated in the oral cavity within 10 seconds
  • the sample 21b disintegrated in the oral cavity within 5 seconds, and there was no grit feeling and minimal irritation.
  • Self-made sample 23a instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Homemade sample 23b instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • Neotame and red iron oxide pass 200 mesh, and other raw materials pass 80 mesh sieve for use;
  • Example 11a Weigh the powder prepared in Example 11a in the prescription amount, anhydrous disodium hydrogen phosphate, mannitol P100SD, crospovidone XL, croscarmellose sodium, sodium starch glycolate, and stearic acid. Place magnesium, neotame, red iron oxide and other materials in a 50ml glass preparation bottle, tighten the cap, mix with a vortex mixer for five minutes, then remove it through an 80-mesh stainless steel sieve, mix with a vortex mixer for five minutes, then take out 80 mesh After the stainless steel sieve, mix with a vortex mixer for five minutes to obtain a tablet premix;
  • Purified water is added to 16 grams to make 40 tablets, each about 0.4 grams, containing about 0.1901 grams of solids
  • the red iron oxide is used after 200 meshes.
  • freeze-dried sample is heat-sealed to obtain a freeze-dried orally disintegrating tablet.
  • the pH and relative exposure test values are:
  • the sample 22a disintegrated in the oral cavity within 10 seconds
  • the sample 22b disintegrated in the oral cavity within 5 seconds, and there was no grit feeling and minimal irritation.
  • Self-made sample 24a Instantaneous stimulation +, disappear within 1-15 minutes after delayed stimulation, and the bitterness is acceptable.
  • Self-made sample 24b instantaneous stimulation +, disappear within 1-15 minutes of delayed stimulation, and the bitterness is acceptable.
  • the powder equivalent to 20 mg of vortioxetine was tested by 10 subjects. The irritation was slight within 1 minute, and the finished product had an acceptable taste.
  • the powder equivalent to 20 mg of vortioxetine was tested by 10 subjects. The irritation was slight within 1 minute, and the finished product had an acceptable taste.
  • Subject Transient stimulation Delayed stimulation (minutes) Bitterness Grit Subject 1 + 1-15 Acceptable no Subject 2 + 1-15 Acceptable no Subject 3 + 1-15 Acceptable no Subject 4 + 1-15 Acceptable no Subject 5 + 1-15 Acceptable no Subject 6 + 1-15 Acceptable no Subject 7 + 1-15 Acceptable no Subject 8 + 1-15 Acceptable no Subject 9 + 1-15 Acceptable no Subject 10 + 1-15 Acceptable no
  • Table 53 Taste test of vortioxetine hydrobromide half salt solid dispersion oral suspension
  • vortioxetine lactate salt vortioxetine hydrobromide mono-salt and vortioxetine hydrobromide half-salt equivalent to 5 mg of vortioxetine respectively over 100 mesh powders directly in front of the upper part of the tongue for one minute.
  • the following table 54 is a comparison of the salt-type taste of different vortioxetine in 30 attempts by 10 subjects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

用于口腔掩味的包衣颗粒、固体分散体、组合物和制剂，其改善了氢溴酸沃替西汀的掩味效果，提高患者的依从性和顺应性。

Description

用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 技术领域
本申请涉及药物制剂技术领域，具体涉及用于口腔掩味的包衣颗粒、固体分散体、组合物和制剂。
背景技术
沃替西汀(又名伏硫西汀)是多靶点抗抑郁药，兼具5-HT 3受体拮抗作用和5-HT 1A受体激动作用，用于重症抑郁症的治疗。目前临床使用的是沃替西汀的氢溴酸盐作为其活性成分，由武田制药公司(Takeda)和灵北公司(Lundbeck)共同研发，2013年09月30日由FDA批准上市，商品名为Brintellix，获批的规格有四种，分别为5mg、10mg、15mg和20mg，剂型为薄膜包衣片。
氢溴酸沃替西汀的化学名为：1-[2-(2,4-二甲基苯硫烷基)苯基]哌嗪氢溴酸盐，英文名为Vortioxetine hydrobromide，分子式为C 18H 22N 2S·HBr。此外，US9562024B2中披露了沃替西汀的氢溴酸半盐化合物，即每两个沃替西汀分子共用一个氢溴酸分子，分子式为C 18H 22N 2S·1/2HBr。C 18H 22N 2S·HBr和C 18H 22N 2S·1/2HBr结构式如下：
Figure PCTCN2020113341-appb-000001
抑郁症是多发疾病，临床需求旺盛。但是抑郁症患者在发病期间，经常拒绝或者不配合治疗，在医护人员和家庭护理人员不注意时吐出服用的药片。普通的片剂和胶囊属于“整体型药片”，精神病人、老年人、长期卧床病人(药片梗在食管中)，服用还有一定的危险。因此，临床需要有更合适的剂型来提高患者的用药依从性或顺应性。口腔分散制剂使药物在口腔中能够以微粒型制剂(例如颗粒剂、散剂、混悬剂、干混悬剂)状态或液体型制剂(例如口服混悬液)状态存在，或者在口腔中能够快速转变为微粒状态或液体状态(例如口腔崩解片、口腔分散片)。口腔分散剂型是最合适的提高抑郁症患者顺应性的技术手段，其中口腔崩解片因为使用方便、携带方便、运输方便、质量稳定，是最佳的剂型。例如阿普***口崩片、奥氮平口崩片和利培酮口崩片等。
由于沃替西汀原料药自身理化特性及临床顺应性多方面的原因，至今少有其它剂型上市。
沃替西汀的氢溴酸盐和欧洲上市的乳酸盐对口腔粘膜均具有很强的刺激性，口腔暴露时会给使用者造成不适，尤其对舌面有强烈的刺激感，即使漱口后，这种刺激感仍然持续 半天甚至更长时间。这样会影响用药的顺应性，限制了其在口腔有暴露的口服制剂的应用。因此，需要制备薄膜包衣片以外的口腔分散剂型口服制剂来克服粘膜刺激性的难题。
通常使用两种方法来克服药物的不良味道。第一种方法为降低药物的溶解度，减少药物在口腔中的暴露量。另一种方法是改变药物与味觉受体相互作用的能力，对味觉相关受体得影响，这会有潜在的未知毒副作用。因此第一种方法对患者是更安全的。为了减少药物在口腔中的刺激，就要降低药物在口腔中的暴露量、降低药物的溶出度；但是，降低药物溶出度的同时，又会减缓药物的吸收，从而影响速释剂型的吸收和代谢速度，影响药效和安全性。这种技术上的矛盾，也是该产品没有口腔掩味速释剂型上市的主要技术障碍。尤其是当患者病情改善，愿意配合服药从而换用普通的速释包衣片之后，两个剂型因为溶出和吸收代谢速度不同，导致患者换药后产生潜在的生理和病理问题。
利用矫味剂矫味也是调节原料药苦涩等不良口感的方法，但是矫味剂对于沃替西汀的刺激性改善的效果很差。
已批准上市的沃替西汀乳酸盐口服液因刺激性强，故上市多年仍未获得市场认可。因此，亟需开发新型适合抑郁患者的掩味口腔暴露型速释制剂，满足临床上个性化用药。
发明内容
为解决沃替西汀对口腔黏膜、舌面的刺激及口感差的问题，本申请的一个或多个实施方式提供了沃替西汀的掩味速释剂型制剂，其通过采用适宜的辅料及制备方法，提高患者的依从性和顺应性。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐的口腔分散制剂，其包含氢溴酸沃替西汀半盐和药物可接受的辅料。
在本申请的一个或多个实施方式中，本申请的口腔分散制剂为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂。
在本申请的一个或多个实施方式中，片剂为口崩片或分散片。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂，其包含氢溴酸沃替西汀半盐或一盐以及药物可接受的掩味辅料。
在本申请的一个或多个实施方式中，在本申请的口腔分散掩味制剂中，所述氢溴酸沃替西汀半盐或一盐被所述掩味辅料包衣，形成包衣颗粒。
在本申请的一个或多个实施方式中，所述包衣颗粒中的所述掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、或聚乙烯醇。
在本申请的一个或多个实施方式中，所述包衣颗粒中的所述掩味辅料中包含碱性辅料。
在本申请的一个或多个实施方式中，所述包衣颗粒中包含抗粘剂。
在本申请的一个或多个实施方式中，口腔分散掩味制剂中的氢溴酸沃替西汀半盐或一盐分散在掩味辅料中，形成固体分散体。
在本申请的一个或多个实施方式中，所述固体分散体中的掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类。在本申请的一个或多个实施方式中，所述固体分散体中的掩味辅料中包含碱性辅料。
在本申请的一个或多个实施方式中，所述固体分散体中的氢溴酸沃替西汀半盐或一盐与碱性辅料混合。
在本申请的一个或多个实施方式中，所述固体分散体中的氢溴酸沃替西汀半盐或一盐与磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺中的至少一种混合，形成组合物。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐或一盐的掩味包衣颗粒，其中所述掩味包衣颗粒的掩味包衣辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、或聚乙烯醇类。
在本申请的一个或多个实施方式中，所述掩味包衣辅料中包含碱性辅料。
在本申请的一个或多个实施方式中，所述掩味包衣辅料中包含抗粘剂。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐或一盐的掩味固体分散体，其中掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类。
在本申请的一个或多个实施方式中，所述掩味辅料中包含碱性辅料。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐或一盐的掩味组合物，其包含氢溴酸沃替西汀半盐或一盐以及碱性辅料。
在本申请的一个或多个实施方式中，所述掩味组合物中的碱性辅料为磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺中的至少一种。
在本申请的一个或多个实施方式中，口腔分散掩味制剂、掩味包衣颗粒、或掩味固体分散体中的甲基丙烯酸共聚物类为聚丙烯酸树脂。
在本申请的一个或多个实施方式中，口腔分散掩味制剂、掩味包衣颗粒、或掩味固体分散体中的聚丙烯酸树脂为聚丙烯酸树脂II或聚丙烯酸树脂IV。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或掩味包衣颗粒中的氢溴酸沃替西汀半盐或一盐被掩味辅料包衣而形成包衣颗粒，所述包衣颗粒进一步分散在掩味辅料中而形成固体分散体；另外，所形成的固体分散体还可进一步与碱性辅料混合。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或固体分散体中的所述氢溴酸 沃替西汀半盐或一盐分散在掩味辅料中而形成固体分散体，所述固体分散体进一步被掩味辅料包衣而形成包衣颗粒；另外，所形成的包衣颗粒还可进一步与碱性辅料混合。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或掩味包衣颗粒中的氢溴酸沃替西汀半盐或一盐被掩味辅料包衣而形成包衣颗粒，所述包衣颗粒进一步与碱性辅料混合。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或固体分散体中的所述氢溴酸沃替西汀半盐或一盐分散在掩味辅料中而形成固体分散体，所述固体分散体进一步与碱性辅料混合。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或掩味包衣颗粒中的掩味包衣辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、或聚乙烯醇类。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或掩味固体分散体中的掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类。
在本申请的一个或多个实施方式中，口腔分散掩味制剂或掩味组合物中的碱性辅料为磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺中的至少一种。
在本申请的一个或多个实施方式中，口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、或掩味组合物中的氢溴酸沃替西汀半盐或一盐与药物可接受的用于形成包衣或固体分散体的掩味辅料的重量比为1:0.1-1:5，例如1:0.3-1:3、1:0.5-1:1.5，又例如1:0.1、1:0.2、1:0.3、1:0.4、1:0.5、1:0.6、1:0.7、1:0.8、1:0.9、1:1、1:2、1:3、1:4或1:5。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀半盐或一盐与药物可接受的碱性辅料的重量比1:0.01-1:1.1，例如1:0.01-1:1，又例如1:0.01、1:0.02、1:0.03、1:0.04、1:0.05、1:0.06、1:0.07、1:0.08、1:0.09、1:0.1、1:0.5、1:1、1:1.1。
在本申请的一个或多个实施方式中，本申请的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、或掩味组合物为晶态或非晶态物质。
在本申请的一个或多个实施方式中，本申请的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、或掩味组合物还包含填充剂、矫味剂、释放调节剂、增塑剂、抗粘剂和/或崩解剂。
在本申请的一个或多个实施方式中，该抗粘剂为滑石粉，其占所述掩味包衣颗粒总重量的5％-25％，例如10％-20％，又例如10％、11％、12％、13％、14％、15％、16％、17％、18％、19％、或20％。
在本申请的一个或多个实施方式中，该矫味剂为纽甜，其占所述口腔分散掩味制剂总重量的0.05％-0.5％，例如0.1％、0.2％、或0.3％。
在本申请的一个或多个实施方式中，该释放调节剂为聚乙二醇或碱性辅料。
在本申请的一个或多个实施方式中，该崩解剂为羧甲淀粉钠、交联羧甲纤维素钠、交联聚维酮及其组合，其占所述口腔分散掩味制剂总重量的1％-8％，优选地2％-6％。
在本申请的一个或多个实施方式中，口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、或掩味组合物为或被制备为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂。在本申请的一个或多个实施方式中，所述片剂为口崩片或分散片。
在本申请的一个或多个实施方式中，口腔分散制剂、口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、或掩味组合物中的氢溴酸沃替西汀半盐或一盐为无定型物或晶体。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀半盐在制备口腔分散剂、掩味包衣颗粒、掩味固体分散体、掩味组合物、或口腔分散掩味制剂中的用途。在本申请的一个或多个实施方式中，所述口腔分散剂或者口腔分散掩味制剂为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂。在本申请的一个或多个实施方式中，所述片剂为口崩片或分散片。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀一盐在制备口腔分散剂、掩味包衣颗粒、掩味固体分散体、掩味组合物、或口腔分散掩味制剂中的用途。在本申请的一个或多个实施方式中，所述制备口腔分散剂或者口腔分散掩味制剂为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂。在本申请的一个或多个实施方式中，所述片剂为口崩片或分散片。
本申请的一个或多个实施方式提供了制备氢溴酸沃替西汀半盐或一盐的掩味包衣颗粒或其制剂的方法，其包括：
(1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；
(2a)将掩味辅料在溶剂中分散，通过流化床将所述氢溴酸沃替西汀半盐或一盐粉末用所述掩味辅料包衣并去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀半盐或一盐；或者(2b)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料加入溶剂形成氢溴酸沃替西汀半盐或一盐的混悬液，通过流化床、喷雾干燥或蒸发去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀半盐或一盐；
(3)任选地，将所述包衣的氢溴酸沃替西汀半盐或一盐制备为制剂。
在本申请的一个或多个实施方式中，在粉碎后过20-300目筛，例如过100、150、或200目筛。
在本申请的一个或多个实施方式中，将掩味辅料和释放调节剂在溶剂中分散。在本申请的一个或多个实施方式中，所述释放调节剂为聚乙二醇或碱性辅料。在本申请的一个或多个实施方式中，所述溶剂为水、乙醇或二氯甲烷；
优选地，所述氢溴酸沃替西汀半盐或一盐粉末、掩味辅料、释放调节剂和增塑剂加入 溶剂形成氢溴酸沃替西汀半盐或一盐的混悬液；更优选地，所述增塑剂为聚乙二醇或枸橼酸三乙酯；优选地，所述溶剂为水、乙醇或二氯甲烷。
本申请的一个或多个实施方式提供了制备氢溴酸沃替西汀半盐或一盐的固体分散体或其制剂的方法，其包括：
(1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；
(2a)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料混合，在50-150℃下加热软化或液化，降温固化，粉碎后得到粉末；或
(2b)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料在溶剂中溶解，通过蒸馏、流化床或喷雾干燥去除溶剂，得到粉末；
(3)任选地，将步骤(2a)或(2b)中得到的粉末制备为制剂。
在本申请的一个或多个实施方式中，在粉碎后过20-300目筛，例如过100、150或200目筛。
在本申请的一个或多个实施方式中，将所述氢溴酸沃替西汀半盐或一盐粉末、掩味辅料和释放调节剂混合。
在本申请的一个或多个实施方式中，所述溶剂为水、乙醇或二氯甲烷。
在本申请的一个或多个实施方式中，所述掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类。
在本申请的一个或多个实施方式中，所述甲基丙烯酸共聚物类为聚丙烯酸树脂。
在本申请的一个或多个实施方式中，聚丙烯酸树脂为聚丙烯酸树脂II或聚丙烯酸树脂IV。
本申请的一个或多个实施方式提供了制备氢溴酸沃替西汀半盐或一盐的掩味组合物或其制剂的方法，其包括：
(1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；
(2)将所述氢溴酸沃替西汀半盐或一盐粉末与碱性辅料混合得到掩味组合物；
(3)任选地，将所述掩味组合物制备为制剂。
优选地，粉碎后过50-300目筛，更优选地过100-200目筛；
优选地，所述碱性辅料为磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺；
在本申请的一个或多个实施方式中，可采用本领域的常规方法将所述粉末制备为常规制剂。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀半盐或一盐与药物可接受的掩味辅料的重量比为1:0.1-1:5，例如1:0.5-1:1.5，1:0.3-1:1.5，1:0.3-1:1.3，又例如1:0.1、1:0.2、 1:0.3、1:0.4、1:0.5、1:0.6、1:0.7、1:0.8、1:0.9、1:1、1:2、1:3、1:4、或1:5；氢溴酸沃替西汀半盐或一盐与药物可接受的碱性辅料的重量比1:0.01-1:1.1，优选地1:0.01-1:1。本申请的一个或多个实施方式提供了包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体，其中所述氢溴酸沃替西汀半盐与聚丙烯酸树脂IV的重量比为1:0.1-1:5，例如1:0.3-1:2，1:0.5-1:1.5，又例如1:0.1、1:0.2、1:0.3、1:0.4、1:0.5、1:0.6、1:0.7、1:0.8、1:0.9、1:1、1:2、1:3、1:4、或1:5。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体，其中所述氢溴酸沃替西汀半盐与聚丙烯酸树脂IV的重量比为1:0.1-1:5，1:0.3-1:2，1:0.5-1:1.5，又例如1:0.1、1:0.2、1:0.3、1:0.4、1:0.5、1:0.6、1:0.7、1:0.8、1:0.9、1:1、1:2、1:3、1:4、或1:5。
在本申请的一个或多个实施方式中，包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体具有图20所示的特征峰。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体具有图22所示的特征峰。
在本申请的一个或多个实施方式中，对于包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体、或者氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体，使用Cu-Kα辐射，以2θ角度表示的X-射线粉末衍射图在以下位置具有特征峰：4.2±0.2°、14.5±0.2°、17.4±0.2°、19.2±0.2°、和22.6±0.2°。
在本申请的一个或多个实施方式中，对于包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体、或者氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体，使用Cu-Kα辐射，以2θ角度表示的X-射线粉末衍射图在以下位置具有特征峰：4.2±0.2°、14.5±0.2°、16.6±0.2°、17.4±0.2°、19.2±0.2°、21.5±0.2°、22.6±0.2°、24.4±0.2°、26.0±0.2°、28.2±0.2°、和29.0±0.2°。
在本申请的一个或多个实施方式中，包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体、或者氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体，还包含PEG 4000、PEG 6000、PEG 8000中的至少一种。在本申请的一个或多个实施方式中，所述聚丙烯酸树脂IV与PEG 4000、PEG 6000、PEG 8000中的至少一种的重量比为1:0.05-1:2，例如1:0.05、1:0.1、1:0.5、1:1、1:1.5、或1:2。
本申请的一个或多个实施方式提供了本申请的氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物在制备抗抑郁药物中的用途。
本申请的一个或多个实施方式提供了本申请的氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物，其用于治疗抑郁症或制备抗抑郁药物。
本申请的一个或多个实施方式提供了治疗抑郁症的方法，该方法包括向有此需要的对象施用前述权利要求中任一项所述的氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物。
具体实施方式
在本申请的一个或多个实施方式中，口腔分散制剂使药物在口腔中能够以微粒型制剂(例如颗粒剂、散剂、混悬剂、干混悬剂)状态或液体型制剂(例如口服悬浮液)状态存在，或者在口腔中能够快速转变为微粒状态或液体状态(例如口腔崩解片、口腔分散片)。
在本申请的一个或多个实施方式中，将氢溴酸沃替西汀粉末用合适的掩味高分子辅料包埋或包衣后得到包衣颗粒，然后按公知的口服制剂制备方法制成口腔分散制剂。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀的口腔分散制剂包含氢溴酸沃替西汀，掩味用聚合物、壳聚糖、脱乙酰基壳聚糖之一的聚合物，及其它辅料，其配比(重量比)为氢溴酸沃替西汀:含二甲氨基乙基单元的聚合物、壳聚糖、或脱乙酰基壳聚糖＝1:0.1-1:5，例如:0.3-1:3。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散制剂还包含抗粘剂以防止掩味包衣颗粒制备过程中的粘结，其配比(占掩味颗粒的总重量)为5％-25％。该抗粘剂可为滑石粉。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散制剂还包含矫味剂，其配比(占制剂的总重量的比)为0.05％-0.5％。矫味剂可为纽甜(Neotame)。
本申请的一个或多个实施方式提供了的第二方案，将氢溴酸沃替西汀与合适的高分子辅料制成晶态或非晶态的固体分散体，然后按公知口服制剂制备方法制成口腔分散制剂。
在本申请的一个或多个实施方式中，该氢溴酸沃替西汀口腔分散掩味制剂，包含氢溴酸沃替西汀、掩味用聚合物、壳聚糖、脱乙酰基壳聚糖之一的聚合物，及其它辅料，其配比(重量比)为氢溴酸沃替西汀:含二甲氨基乙基单元的聚合物、壳聚糖、或脱乙酰基壳聚糖＝1:0.3-1:5。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂还包含矫味剂，其配比(占制剂的总重量的比)为0.05％-0.5％。该矫味剂可为纽甜(Neotame)。
本申请的一个或多个实施方式提供了的第三方案，用弱碱性辅料，短时改变药物分散在口腔局部的pH环境，造成口腔内溶出在刺激阈值以下，在胃液中恢复到酸性的pH环境，同时解决了口腔暴露和胃肠道内溶出与吸收代谢的问题。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂包含氢溴酸沃替西汀、碱性或弱碱性掩味剂和矫味剂。其配比(重量比)为氢溴酸沃替西汀矫味剂＝1:(0.0001-0.01)，例如1:(0.0009-0.009)。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂中的掩味剂为可供药用碱性辅料，包括但不限于磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂中的矫味剂为可供药用的矫味剂，包括但不限于纽甜(Neotame)。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀的掩味包衣颗粒或掩味固体分散体可被制备为用于口腔分散的氢溴酸沃替西汀口服制剂。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀的掩味包衣颗粒或掩味固体分散体的口腔暴露或分散制剂包括但不限于在口腔中能够以微粒型制剂(例如颗粒剂、散剂、混悬剂、干混悬剂)状态或溶液型制剂(例如口服溶液)状态存在，或者在口腔中能够快速转变为微粒状态或溶液状态(例如口腔崩解片、口腔分散片)。。
本申请的一个或多个实施方式提供了氢溴酸沃替西汀药物的掩味制剂的制备方法，其至少包括三种方法。
方法一：
(1)将氢溴酸沃替西汀粉碎得到氢溴酸沃替西汀粉末；优选地在粉碎后过20-300目筛，更优选地过100-200目筛；
(2a)将掩味辅料在溶剂中分散，通过流化床将所述氢溴酸沃替西汀粉末用所述掩味辅料包衣并去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀；优选地，将掩味辅料和释放调节剂在溶剂中分散；更优选地，所述释放调节剂为聚乙二醇或碱性辅料；优选地，所述溶剂为水、乙醇或二氯甲烷；或者
(2b)将所述氢溴酸沃替西汀粉末和掩味辅料加入溶剂形成混悬液，通过流化床、喷雾干燥或蒸发去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀；优选地，所述氢溴酸沃替西汀粉末、掩味辅料、和/或释放调节剂和增塑剂加入溶剂形成氢溴酸沃替西汀的混悬液；优选地，所述增塑剂为聚乙二醇或枸橼酸三乙酯；优选地，所述溶剂为水、乙醇或二氯甲烷；
(3)任选地，将所述包衣的氢溴酸沃替西汀制备为制剂。
方法二：
(1)将氢溴酸沃替西汀粉碎得到氢溴酸沃替西汀粉末；优选地在粉碎后过20-300目筛，更优选地过100-200目筛；
(2a)将所述氢溴酸沃替西汀粉末和掩味辅料混合，在50-150℃下加热软化或液化，降温固化，粉碎后得到粉末；优选地，将所述氢溴酸沃替西汀粉末、掩味辅料和释放调节剂混合；或
(2b)将所述氢溴酸沃替西汀粉末和掩味辅料在溶剂中溶解，通过蒸馏、流化床或喷 雾干燥去除溶剂，得到粉末；优选地，所述溶剂为水、乙醇或二氯甲烷；
(3)任选地，将步骤(2a)或(2b)中得到的粉末制备为制剂。
方法三：
(1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；优选地，粉碎后过50-300目筛，更优选地过100-200目筛；
(2)将所述氢溴酸沃替西汀半盐或一盐粉末与碱性辅料混合得到掩味组合物；优选地，所述碱性辅料为磷酸三钠、磷酸氢二钠、碳酸钠、碳酸氢钠、枸橼酸三钾、乙酸钠、氢氧化钙、或葡甲胺；
(3)任选地，将所述掩味组合物制备为制剂。
在本申请的一个或多个实施方式中，上述方法中可采用氢溴酸沃替西汀的半盐或一盐，可采用无定型或晶态的氢溴酸沃替西汀半盐或一盐。
在本申请的一个或多个实施方式中，上述三种制备方法三可独立实施，也可以相互组合实施，还可按公知的制剂制备工艺组合实施。
在本申请的一个或多个实施方式中，上述制备方法中的释放调节剂包括但不限于甘露醇、山梨醇、木糖醇、聚乙二醇、羟丙纤维素、和/或羟丙甲纤维素。
在本申请的一个或多个实施方式中，上述制备方法中的增塑剂包括但不限于聚乙二醇和/或枸橼酸三乙酯。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂的制备方法，采用药物可接受的一种或多种树脂与氢溴酸沃替西汀共溶于药物可接受的一种或多种溶剂，得到真溶液，该溶液经旋转蒸发、喷雾干燥或流化床制粒去除溶剂后，在聚合物的限制空间内得到微晶态的氢溴酸沃替西汀固体分散体；按常规的制剂工艺，加入处方量的其它公知的辅料，再用小分子碱性材料掩味，也可制备口腔暴露型氢溴酸沃替西汀口腔分散掩味制剂。
在本申请的一个或多个实施方式中，采用聚丙烯酸树脂IV与氢溴酸沃替西汀一盐或半盐在溶剂中溶解，氢溴酸沃替西汀一盐或半盐与聚丙烯酸树脂IV的重量比为1:0.1-1:5，优选地1:0.3-1:2，更优选地1:0.5-1:1.5。去除溶剂后得到固体分散体，粉末晶体衍射特征峰：4.2±0.2°、14.5±0.2°、17.4±0.2°、19.2±0.2°、和22.6±0.2°；更进一步地，粉末晶体衍射特征峰：4.2±0.2°、14.5±0.2°、16.6±0.2°、17.4±0.2°、19.2±0.2°、21.5±0.2°、22.6±0.2°、24.4±0.2°、26.0±0.2°、28.2±0.2°、和29.0±0.2°。该固体分散体经稳定性研究证明溶出稳定，杂质稳定，晶态稳定。
在本申请的一个或多个实施方式中，沃替西汀口腔分散掩味制剂的制备方法采用药物可接受的一种和多种树脂与氢溴酸沃替西汀共溶于药物可接受的一种或多种溶剂，然后降低溶液的溶解性或者去除溶剂，沃替西汀与树脂形成固体分散体及其颗粒；按常规的制剂 工艺，加入处方量其它公知的辅料，可制备氢溴酸沃替西汀口腔分散掩味制剂；其中沃替西汀以离子或分子状态存在于树脂，并与树脂中的官能团形成相互作用，从而在口腔环境中解离减慢、在经过胃液的环境后，能在胃肠道中快速解离成沃替西汀。
在本申请的一个或多个实施方式中，采用药物可接受的一种和多种树脂与氢溴酸沃替西汀半盐或一盐共溶于药物可接受的一种或多种溶剂，然后降低溶液的溶解性(例如加入不良溶剂，或者降低温度)或者去除溶剂，得到非晶态的氢溴酸沃替西汀固体分散体；按常规的制剂工艺，加入处方量其它公知的辅料，可以选择性的在外加辅料中加入碱性辅料混合，碱性辅料可以改变黏膜和味蕾上受体的微环境，减轻刺激感；其中氢溴酸沃替西汀以无定型聚集状态存在。
在本申请的一个或多个实施方式中，树脂包括但不限于聚丙烯酸树脂类(L、S型或II型、III型、IV型)、含官能团-NH 2、NR 2、-COOH、-COO -、-SO 3H、或-SO 3 -的甲基丙烯酸树脂类、二乙烯基苯类树脂类及聚苯乙烯树脂类型的线形高分子材料。
在本申请的一个或多个实施方式中，氢溴酸沃替西汀口腔分散掩味制剂的制备方法将药物可接受的一种和多种掩味辅料、药物可接受的一种和多种释放调节剂与氢溴酸沃替西汀混合均匀后，用热熔制粒及热熔挤出的工艺制备固体分散体后，按常规的制剂工艺，加入处方量其它公知的辅料；固体分散体可以再用碱性掩味辅料混合，也可以进一步用掩味辅料包衣。该氢溴酸沃替西汀口腔分散掩味制剂在口腔环境中释放缓慢或不释放、在经过胃液的环境后，能在胃肠道中快速解离成氢溴酸沃替西汀，被胃肠道吸收。
在本申请的一个或多个实施方式中，碱性线性高分子材料包括但不限于聚丙烯酸树脂类(例如II型或IV型)、壳聚糖、或氨基糖聚合物。
在本申请的一个或多个实施方式中，所述释放调节剂包括但不限于甘露醇、山梨醇、不糖醇、聚乙二醇、羟丙纤维素、或羟丙甲纤维素。
发明人意外发现，沃替西汀半盐(C 18H 22N 2S·1/2HBr)比沃替西汀一盐(C 18H 22N 2S·HBr)的刺激性显著降低，即使折算成完全相同的C 18H 22N 2S量，也是如此。两者在模拟口腔环境pH 6.8的醋酸钠介质中，溶解度差别不大(采用美国药典通则方法检测，沃替西汀一盐的溶解度为0.15mg/ml；沃替西汀半盐的溶解度0.14mg/ml)，但是沃替西汀半盐的刺激性显著降低。
因为沃替西汀半盐的口腔和舌部刺激性更低，可以和高分子辅料制备成固体分散体，大大提高沃替西汀在胃肠道中的溶出速度和总溶出量，同时又能保持无口腔刺激。
崩解速度是口腔崩解片的重要临床指标，各国药典均推荐不大于1分钟，临床实践是越快越好，尤其对于存在患者顺应性问题的药物。冻干型的口腔崩解片可采用冷冻干燥技术，药物活性成分以微粉或溶液状态均匀分散骨架材料溶液中，定量分装、冷冻干燥后的制成品可在5秒以内崩解；但工艺复杂，产业化难度大。压制型的口腔崩解片采用通用的 片剂制备技术，通过使用高效崩解剂及减小压片压力，也能达到1分钟的崩解时限；但减小压片压力会很大程度上影响片剂的强度，生产、运输及使用过程中因磨损破碎会有诸多的不便；研究人员通过多种崩解剂联合使用，得到的复合崩解剂已能确保制成品在片剂的正常强度范围内，控制崩解在10秒以内。
在本申请的一个或多个实施方式中，复合崩解剂包括但不限于羧甲淀粉钠、交联羧甲纤维素钠及交联聚维酮。
在本申请的一个或多个实施方式中，羧甲淀粉钠、交联羧甲纤维素钠及交联聚维酮的重量比为1:1:1，在制剂中的重量比分别为1％-8％，例如2％-6％。
在本申请的一个或多个实施方式中，本申请使用公认为安全的聚合物。该类聚合物目前公知的成型产品主要有聚丙烯酸树脂II型和聚丙烯酸树脂IV型(尤特奇E型)，其中尤特奇E型英文商品名Eudragit E，通用名为Amino Methacrylate Copolymer，已被美国药典USP40-NF35版收载，FDA明确在用于口崩片掩味时该聚合物的最大日用量为214.28mg，能满足氢溴酸沃替西汀掩味的需求，其类似物尤释E100具有相同的化学结构理化特性及质量标准，也能满足制备的需要。
在本申请的一个或多个实施方式中，通过选择性加入矫味剂矫味，进一步改善口味，同时提供各种口味选择。该技术中用到的矫味剂之一是纽甜(Neotame)，已被美国药典USP40-NF35版收载，纽甜已作为食品添加剂广泛使用。
在本申请的一个或多个实施方式中，使用碱性辅料掩味剂，能够明显减轻其对舌部的刺激性，刺激可以减轻到临床用药可接受的程度。
在本申请的一个或多个实施方式中，使用的掩味剂是药用可接受的辅料。
本申请的一个或多个实施方式提供的制剂可提高患者的依从性和顺应性、提高氢溴酸沃替西汀的溶出性，潜在提高药物的生物利用度，解决现有技术中沃替西汀口服制剂剂型单一，未适应临床差异化、个性化给药需要的缺点。
本申请发明人对市售的氢溴酸沃替西汀薄膜包衣片进行了研究：单次使用20mg，10mg及5mg规格，口腔分散后都有明显的苦涩和长时间强烈的延后刺激感。口腔刺激限制了其除薄膜包衣片外的其它口服制剂的开发及临床应用。
附图说明
图1：氢溴酸沃替西汀半盐X射线粉末衍射图。
图2：氢溴酸沃替西汀一盐(α型)X射线粉末衍射图。
图3：氢溴酸沃替西汀一盐(β型)X射线粉末衍射图。
图4：尤释E100:PEG6000＝1:0.23喷雾干燥后X射线粉末衍射图。
图5：氢溴酸沃替西汀半盐:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射 图。
图6：氢溴酸沃替西汀一盐α型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射图。
图7：氢溴酸沃替西汀一盐β型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射图。
图8：氢溴酸沃替西汀一盐在0.1N盐酸中紫外扫描图。
图9：尤特奇E PO在0.1N盐酸中的紫外扫描图。
图10：氢溴酸沃替西汀一盐:尤特奇E PO＝1:0.5混合粉末在0.1N盐酸中的紫外扫描图。
图11：氢溴酸沃替西汀一盐:尤特奇E PO＝1:0.5混合热熔粉末在0.1N盐酸中的紫外扫描图。
图12：氢溴酸沃替西汀半盐在0.1N盐酸中紫外扫描图。
图13：氢溴酸沃替西汀半盐:尤特奇E PO＝1:1.5直接混合粉末在0.1N盐酸中的紫外扫描图。
图14：氢溴酸沃替西汀半盐:尤特奇E PO＝1:1.5热熔粉末在0.1N盐酸中的紫外扫描图。
图15：氢溴酸沃替西汀半盐:尤特奇E PO＝1:5直接混合粉末在0.1N盐酸中的紫外扫描图。
图16：氢溴酸沃替西汀半盐:尤特奇E PO＝1:5混合的热熔后粉末在0.1N盐酸中的紫外扫描图。
图17：聚丙烯酸树脂IV在0.1N盐酸中的紫外扫描图。
图18：氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:1.5的直接混合粉末在0.1N盐酸中的紫外扫描图。
图19：氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:1.5热熔粉末在0.1N盐酸中的紫外扫描图。
图20：氢溴酸沃替西汀半盐-聚丙烯酸树脂IV的固体分散体X射线粉末衍射图。
图21：聚丙烯酸树脂IV喷雾干燥后X射线粉末衍射图。
图22：氢溴酸沃替西汀一盐-聚丙烯酸树脂IV的固体分散体X射线粉末衍射图。
图23：氢溴酸沃替西汀一盐:聚丙烯酸树脂II＝1:1.5固体分散体X射线粉末衍射图。
图24：聚丙烯酸树脂II(乙醇旋蒸)X射线粉末衍射图。
图25：氢溴酸沃替西汀半盐:聚丙烯酸树脂II＝1:1.5固体分散体X射线粉末衍射图。
实施例
下面结合具体实施例对本申请的实施方案进行详细描述，但是本领域技术人员应理解，实施例仅用于说明本申请，而不应视为限定本申请的范围。
实施例中未注明具体条件者，按照常规条件、制造商或供应商建议的条件进行。所用试剂或仪器未注明生产厂商和具体型号者，均为可以通过市购获得的常规产品。
对于本文的聚丙烯酸树脂II，其欧洲药典命名为Methyl methacrylate-methacrylic acid copolymer(1:1)，美国药典命名为Methacrylic Acid Copolymer Type A，中国药典命名为聚丙烯酸树脂II，例如，其可购自供应商罗姆公司(例如，商品名为尤特奇L、尤特奇L100、尤特奇L PO)或安徽山河药用辅料有限公司(例如，产品名为聚丙烯酸树脂II)。
对于本文中的聚丙烯酸树脂IV，其美国药典命名为Amino Methacrylate Copolymer，中国药典命名为聚丙烯酸树脂IV，例如，其可购自供应商罗姆公司(例如，商品名为尤特奇E100、尤特奇E PO)、广州茂丰药用辅料有限公司(例如，商品名为尤释E、尤释E100)或安徽山河药用辅料有限公司(例如，产品名聚丙烯酸树脂IV)。
对于其他聚丙烯酸树脂，其可购自例如罗姆公司，例如，商品名为尤特奇RL100、尤特奇L100、尤特奇RS PO、尤特奇S100。实施例中使用的辅料并非本专利关联的辅料，采用本专利制备制剂时，可根据剂型、制剂稳定性及临床使用的需要采用其它公知的普通及功能性药用辅料。实施例中氢溴酸沃替西汀一盐未注明具体使用晶型者，表示α、β或γ晶型均可。
实验中所用的仪器：
X射线粉末衍射(XRD)所使用的仪器为D/max-2200/pc，配置有θ-2θ测角仪RINT2000 Vertical goniometer、MO单色仪、Scintillation counter探测器。采集软件是XG operation。仪器用仪器自带的单晶硅标准品校准。检测条件为：2θ扫描角度范围为3-40°或3-50°，步长0.02°，速度6°/分钟。检测过程：采用铜靶波长为1.54nm的KαX-射线，在40kV和20mA的操作条件下，样品在室温条件下测试，把需要的样品放在Si P无反射板上。样品在检测前过筛。
紫外可见分光光度计：UV-2600型，日本岛津。
分析天平：AUW120D，SHIMADZU。
旋转蒸发仪：R205，台州市信力电子设备有限公司。
热风循环烘箱：DHG-9070A型，上海一恒科学仪器有限公司。
漩涡混合机：Vortex-2上海沪析实业有限公司。
多功能流化床：BWF-1G，重庆英格造粒包衣技术有限公司。
真空冷冻干燥机：FD-2D，北京博医康实验仪器有限公司。
旋转压片机：ZP8，上海信源制药机械有限公司。
高效包衣机：Labcoating IV，深圳市信宜特科技有限公司。
干法制粒机：GL-5B，浙江明天机械有限公司。
整粒机：P100，深圳市信宜特科技有限公司。
便携式pH计：STARTER 300型。
冷冻干燥干机：SCIENT2-30F，宁波新芝生物科技股份有限公司。
平板式泡罩包装机：浙江明天机械有限公司。
相关数据采集方法：
酸碱度及暴露量(以沃替西汀计)检测法：取本品一片(或相当于沃替西汀20mg的粉末)，加纯化水5.0克，36±2℃密闭振摇分散后孵于5分钟，放冷至室温，检测混悬液pH值，用0.22um微孔滤膜滤过，取续滤液2.0ml用纯化水稀释至10ml，作为供试溶液，另取用纯化水定量稀释成10ug/ml(以沃替西汀计)的溶液作为对照溶液，UV法在226nm波长处分别检测吸收值，计算沃替西汀溶出浓度及相对溶出量。
Figure PCTCN2020113341-appb-000002
滴定法测氢溴酸沃替西汀溴含量检测方法：
先配制0.1mol/L的硝酸银滴定液，再配制5mg/ml的曙红Y试液。取0.3g样品加60mL甲醇溶解，然后加入20mL水、20mL冰醋酸和8滴曙红Y试液，用硝酸银滴定液滴定至终点(粉红色)。进行一个空白测试。计算公式：
Figure PCTCN2020113341-appb-000003
其中，
V S＝样品消耗的0.1mol/mL硝酸银滴定液的体积，mL
V b＝空白消耗的体积，mL
N＝硝酸银滴定液的当量浓度
W＝样品重量，mg
水％＝样品的水分
7.990＝每mL的0.1mol/mL硝酸银滴定液相当于7.990mg的Br
在实施例中，掩味效果是通过受试者对于受试样品对口腔、舌部的苦涩感和刺激性的感受进行评价的。
受试者尝试口感、刺激的分级：
Figure PCTCN2020113341-appb-000004
制备例1 沃替西汀游离碱制备
参照专利文献WO2007/144005A1实施例24的制备方法合成沃替西汀。具体为：氮气保护下想500mL四口烧瓶中依次加入200mL甲苯、40.76g叔丁醇钠、0.33g Pd(dba) 2[二(二亚苄基丙酮)钯]和0.68g rac-BINAP(2,2’-双(二苯膦)-1,1’-联萘)，开动搅拌，再加入19.54g 2,4-二甲基苯硫酚，析出白色沉淀，加入42.00g 2-溴碘代苯，升温回流反应5小时，冷却到室温，过滤，除去不溶物，滤液倒回500mL四口烧瓶中，加入42.20g无水哌嗪、40.76g叔丁醇钠、0.33g Pd(dba) 2和0.68g rac-BINAP，回流反应2小时，反应完成。
冷却至室温，加入100mL水萃取，有机相过滤，滤液用3×80mL饱和食盐水洗涤，有机相加热到70℃，加入16.50mL 48％的氢溴酸(145.9mmol)和8.3mL水，搅拌30分钟，冷却到室温，保温2小时，过滤，甲苯洗涤，抽干，滤饼在50℃下真空干燥10小时，得到40.18g类白色固体1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪氢溴酸盐，即氢溴酸沃替西汀盐，摩尔收率75％。
将上步所得的40.18g氢溴酸沃替西汀盐溶液200mL水中，加入200mL二氯甲烷，用15％的氢氧化钠水溶液调节pH 9-10，保温30分钟，静置分层，水相用100mL二氯甲烷萃取一次，合并有机相，100mL水洗涤，有机相分离，加入5g无水硫酸钠干燥，过滤，滤液浓缩干溶剂，得到类白色晶体1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪29.7g，即沃替西汀游离碱，摩尔收率94.0％。
制备例2 氢溴酸沃替西汀半盐制备
参照专利US9562024B2实施例1的合成方法制备氢溴酸沃替西汀半盐。具体为：取8.00g(26.8mmol)沃替西汀置于250mL的圆底烧瓶中，加入122mL乙醇后超声溶解；取2.70g氢溴酸(浓度为40％重量比，13.3mmol)，加入16mL乙醇后超声溶解；搅拌条件下，将氢溴酸的乙醇溶液缓慢滴加至沃替西汀的乙醇溶液中，滴加过程中有固体析出，40℃旋干除去溶剂，40℃真空干燥24小时，得到8.91g(13.1mmol)白色固体氢溴酸沃替西汀半盐，产率98.5％。滴定法测得的溴含量为11.60％。
制备例3 氢溴酸沃替西汀一盐α晶型制备
参照专利文献WO2007/144005A1实施例4a的制备方法合成沃替西汀一盐α晶型。具体为：将2.0g 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪溶解于30mL的热的乙酸乙酯中，并加入0.73mL 48％-wt的氢溴酸水溶液。反应液形成了浓稠的料液，为了适于搅拌，另外加入10mL的乙酸乙酯，将所得的料液在室温下搅拌1小时。过滤料液，并在真空下干燥(20℃)过夜，产生2.0g白色固体产物，收率80％。该产物即为氢溴酸沃替西汀一盐的α晶型产物。滴定法测得的溴含量为20.76％。
制备例4 氢溴酸沃替西汀一盐β晶型制备
参照专利文献WO2007/144005A1实施例4c的制备方法合成沃替西汀一盐α晶型。具体为：将49.5g 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪溶解于500mL的乙酸乙酯中，并加入18.5mL 48％-wt的氢溴酸水溶液。反应液形成了浓稠的料液，将该料液在室温下搅拌过夜。过滤，并在真空下干燥(50℃)过夜，生产29.6g的白色固体产物，收率47％。该产物即为氢溴酸沃替西汀一盐的β晶型产物。滴定法测得的溴含量为20.69％。
制备例5 氢溴酸沃替西汀一盐γ晶型制备
参照专利文献WO2007/144005A1实施例4e的制备方法合成沃替西汀一盐γ晶型。具体为：将1g 1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪氢溴酸盐溶解于20mL水中并加热至85℃，反应液基本澄清，滴加1滴HBr水溶液使之澄清。加入HBr水溶液直到观察到浊点产生。溶液冷却至室温过滤并干燥。该产物即为氢溴酸沃替西汀一盐的γ晶型产物。滴定法测得的溴含量为20.73％。
实施例1 氢溴酸沃替西汀+包衣材料掩味粉末制备
1a)氢溴酸沃替西汀半盐:尤释E100:PEG6000＝1:0.3:0.07掩味粉末制备
取30.00克尤释E100、7.00克PEG 6000加入至470.02克药用乙醇中，搅拌溶解后备用。
取100-200目氢溴酸沃替西汀半盐100.00克、粒径小于325目滑石粉10.00克置按底喷包衣模式安装的BWF-1G多功能流化床内，调整进风量及导流筒高度，使物料呈流化状态，设置进风温度50-55℃、蠕动泵转速5rpm、雾化压力1.0-1.5atm，喷入制备好的尤释包衣液，喷雾结束，持续流化30分钟后，停止加热，待物料温度降至室温，收集物料，筛分收集粒径60-150目粉末，得掩味粉末125.79克，得率为85.57％，检测粉末含量为60.14％(以沃替西汀计)。
若制备过程中物料粘结，可停机后加入适量滑石粉，保证物料处于流化状态。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表1：
表1 氢溴酸沃替西汀半盐掩味粉末口感测试
Figure PCTCN2020113341-appb-000005
Figure PCTCN2020113341-appb-000006
氢溴酸沃替西汀半盐:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射图见图5，尤释E100:PEG6000＝1:0.23喷雾干燥后X射线粉末衍射图为图4。
1b)氢溴酸沃替西汀一盐α型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末制备
取30.09克尤释E100、7.05克PEG 6000加入至470.20克药用乙醇中，搅拌溶解后备用。
取100-200目氢溴酸沃替西汀一盐α型100.02克、粒径小于325目滑石粉10.05克置按底喷包衣模式安装的BWF-1G多功能流化床内，调整进风量及导流筒高度，使物料呈流化状态，设置进风温度50-55℃、蠕动泵转速5rpm、雾化压力1.0-1.5atm，喷入制备好的尤释包衣液，喷雾结束，持续流化30分钟后，停止加热，待物料温度降至室温，收集物料，筛分收集粒径60-150目粉末，得掩味粉末127.81克，得率为86.82％，检测粉末含量为52.77％(以沃替西汀计)。
若制备过程中物料粘结，可停机后加入适量滑石粉，保证物料处于流化状态。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐α型100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表2：
表2 氢溴酸沃替西汀一盐α型掩味粉末口感测试
Figure PCTCN2020113341-appb-000007
氢溴酸沃替西汀一盐α型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射图见图6，尤释E100:PEG6000＝1:0.23喷雾干燥后X射线粉末衍射图为图4。
1c)氢溴酸沃替西汀一盐β型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末制备
取30.00克尤释E100、7.00克PEG 6000加入至470.20克药用乙醇中，搅拌溶解后备用。
取100-200目氢溴酸沃替西汀一盐β型100.00克、粒径小于325目滑石粉10.00克置按底喷包衣模式安装的BWF-1G多功能流化床内，调整进风量及导流筒高度，使物料呈流化状态，设置进风温度50-55℃、蠕动泵转速5rpm、雾化压力1.0-1.5atm，喷入制备好的尤释包衣液，喷雾结束，持续流化30分钟后，停止加热，待物料温度降至室温，收集物料，筛分收集粒径60-150目粉末，得掩味粉末126.78克，得率为86.24％，检测粉末含量为53.13％(以沃替西汀计)。
若制备过程中物料粘结，可停机后加入适量滑石粉，保证物料处于流化状态。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐β型100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表3：
表3 氢溴酸沃替西汀一盐β型掩味粉末口感测试
Figure PCTCN2020113341-appb-000008
氢溴酸沃替西汀β型:尤释E100:PEG6000＝1:0.3:0.07掩味粉末X射线粉末衍射图见图7，尤释E100:PEG6000＝1:0.23喷雾干燥后X射线粉末衍射图为图4。
1d)氢溴酸沃替西汀半盐:乙基纤维素N10:PEG6000＝1:3:0.07掩味粉末制备
取150.00克乙基纤维素N10、3.50克PEG 6000加入至1500.00克药用乙醇中，搅拌溶解后备用。
取100-200目氢溴酸沃替西汀半盐50.00克、粒径小于325目滑石粉25.00克置按底喷包衣模式安装的BWF-1G多功能流化床内，调整进风量及导流筒高度，使物料呈流化状态，设置进风温度50-55℃、蠕动泵转速5rpm、雾化压力1.0-1.5atm，喷入制备好的尤释包衣液，喷雾结束，持续流化30分钟去除残留乙醇后，停止加热，待物料温度降至室温，收集物料，筛分收集粒径60-150目粉末，得掩味粉末162.91克，得率为71.30％，检测粉末 含量为19.57％(以沃替西汀计)。
若制备过程中物料粘结，可停机后加入适量滑石粉，保证物料处于流化状态。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表4：
表4 氢溴酸沃替西汀半盐掩味粉末口感测试
Figure PCTCN2020113341-appb-000009
1e)氢溴酸沃替西汀半盐:尤特奇RL100:葡甲胺＝1:3:0.07掩味粉末制备
取150.00克尤特奇RL100、3.50克葡甲胺加入至1500.00克药用乙醇中，搅拌溶解后备用。
取100-200目氢溴酸沃替西汀半盐50.00克、粒径小于325目滑石粉25.00克置按底喷包衣模式安装的BWF-1G多功能流化床内，调整进风量及导流筒高度，使物料呈流化状态，设置进风温度50-55℃、蠕动泵转速5rpm、雾化压力1.0-1.5atm，喷入制备好的尤释包衣液，喷雾结束，持续流化30分钟去除残留乙醇后，停止加热，待物料温度降至室温，收集物料，筛分收集粒径60-150目粉末，即得。
若制备过程中物料粘结，可停机后加入适量滑石粉，保证物料处于流化状态。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表5：
表5 氢溴酸沃替西汀半盐掩味粉末口感测试
Figure PCTCN2020113341-appb-000010
Figure PCTCN2020113341-appb-000011
实施例2 氢溴酸沃替西汀+包衣材料掩味粉末制备
2a)氢溴酸沃替西汀半盐:尤释E100＝1:0.7掩味粉末制备
取7.73克尤释E100加入至77.20克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.02克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，筛分收集粒径小于80目粉末，得掩味粉末7.81克，得率为43.98％，检测粉末含量为48.63％(以沃替西汀计)。
剩余物料轻度研磨后筛分收集粒径小于80目粉末，得掩味粉末6.23克，得率为35.08％(以沃替西汀计)，检测粉末含量为49.38％(以沃替西汀计)。
分别取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善较多。
两种掩味粉末混合后，取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善较多。
自制样品1：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品2：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制混合样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表6：
表6 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000012
Figure PCTCN2020113341-appb-000013
2b)氢溴酸沃替西汀一盐:尤释E100:PEG6000＝1:0.77掩味粉末制备
取7.70克尤释E100加入至77.10克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀一盐10.00克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，筛分收集粒径小于80目粉末，得掩味粉末6.98克，得率为39.44％，检测粉末含量为44.63％(以沃替西汀计)。
剩余物料轻度研磨后筛分收集粒径小于80目粉末，得掩味粉末5.93克，得率为33.50％，检测粉末含量为45.38％(以沃替西汀计)。
分别取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明刺激改善较多。
两种掩味粉末混合后，取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善较多。
自制样品1：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品2：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制混合样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表7：
表7 氢溴酸沃替西汀一盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000014
2c)氢溴酸沃替西汀半盐:醋酸纤维素:PEG6000＝1:0.7:0.07掩味粉末制备
取7.00克醋酸纤维素、0.70克PEG6000加入至70.20克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.00克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，筛分收集粒径小于80目粉末，得掩味粉末6.97克，得率为40.76％，检测粉末含量为47.93％(以沃替西汀计)。
剩余物料轻度研磨后筛分收集粒径小于80目粉末，得掩味粉末6.00克，得率为33.90％(以沃替西汀计)，检测粉末含量为48.98％(以沃替西汀计)。
分别取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善较多。
两种掩味粉末混合后，取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善较多。
自制样品1：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品2：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制混合样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表8：
表8 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000015
2d)氢溴酸沃替西汀半盐:聚乙烯醇(低粘度)＝1:0.7掩味粉末制备
取7.00克聚乙烯醇(低粘度)加入至100.00克纯化水中，90℃水浴搅拌溶解，放冷至室温后，加入枸橼酸钾0.07克，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.00克加入至上述溶液中，搅拌分散，过100目 不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量30-33m 3、进风温度60-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，轻度研磨后筛分收集粒径小于80目粉末，得掩味粉末12.79克，得率为75.24％，检测粉末含量为50.99％(以沃替西汀计)。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的沃替西汀氢溴酸半盐100目粉末进行对比，证明刺激改善较多。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表9：
表9 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000016
实施例3 氢溴酸沃替西汀半盐:包衣材料＝1:1掩味粉末制备
3a)氢溴酸沃替西汀半盐:尤特奇E100:PEG6000＝1:1:0.07掩味粉末制备
取10.00克尤特奇E100、0.70克PEG6000加入至70.00克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.01克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，轻度研磨筛分收集粒径小于80目粉末，得掩味粉末13.78克，得率为66.54％，检测含量为41.79％(以沃替西汀计)。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善很大，几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表10：
表10 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000017
3b)氢溴酸沃替西汀半盐:尤特奇L100:PEG6000＝1:1:0.07掩味粉末制备
取10.00克尤特奇L100、0.70克PEG6000加入至70.00克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.00克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，轻度研磨筛分收集粒径小于80目粉末，得掩味粉末14.14克，得率为68.31％，检测含量为42.01％(以沃替西汀计)。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激改善很大，几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表11：
表11 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000018
Figure PCTCN2020113341-appb-000019
3c)氢溴酸沃替西汀半盐:共聚维酮AV64＝1:1掩味粉末制备
取10.00克共聚维酮AV64、加入至70.00克药用乙醇中，搅拌溶解后备用。
取过200目的氢溴酸沃替西汀半盐10.00克加入至上述溶液中，搅拌分散，过100目不锈钢筛网后，收集物料，持续搅拌防止沉集。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入制备好的混悬物料，随时观察物料状态，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，轻度研磨筛分收集粒径小于80目粉末，得掩味粉末14.16克，得率为70.80％，检测含量为42.78％(以沃替西汀计)。
取相当于20mg沃替西汀的掩味粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的沃替西汀氢溴酸半盐100目粉末进行对比，证明刺激改善很大，几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表12：
表12 氢溴酸沃替西汀半盐掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000020
实施例4 氢溴酸沃替西汀:尤特奇＝1:0.5混合物制备
4a)氢溴酸沃替西汀半盐:尤特奇E PO＝1:0.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀半盐5.00克、尤特奇E PO 2.50克，置洁净干燥的50ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得 到1:0.5的混合物粉末。
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表13：
表13 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000021
4b)氢溴酸沃替西汀一盐:尤特奇E PO＝1:0.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀一盐5.00克、尤特奇E PO 2.50克，置洁净干燥的50ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1:0.5的混合物粉末。
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表14：
表14 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000022
Figure PCTCN2020113341-appb-000023
紫外扫描图显示处理后的物料沃替西汀的最大吸收波长及峰强度无明显变化，结果见图8、图9、图10和图11。
4c)氢溴酸沃替西汀一盐:尤特奇RS PO＝1:0.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀一盐5.00克、尤特奇RS PO 2.50克，置洁净干燥的50ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1:0.5的混合物粉末。
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明刺激有所改善。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表15：
表15 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000024
实施例5 氢溴酸沃替西汀半盐:尤特奇E PO＝1:1.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀半盐5.00克、尤特奇E PO 7.50克，置洁净干燥的50ml螺口玻璃试剂瓶中、用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半 流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1:1.5的混合物粉末。
取相当于20mg沃替西汀的1:1.5的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激明显改善。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表16：
表16 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000025
紫外扫描图显示处理后的物料沃替西汀的最大吸收波长及峰强度无明显变化，结果见图9、图12、图13和图14。
实施例6 氢溴酸沃替西汀半盐:尤特奇E PO＝1:5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀半盐5.00克、尤特奇E PO 25.00克，置洁净干燥的100ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1：5的混合物粉末，含量检测为14.39％(以沃替西汀计)。
取相当于20mg沃替西汀的1:5的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明几乎感觉不到刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表17：
表17 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000026
Figure PCTCN2020113341-appb-000027
紫外扫描图显示处理后的物料沃替西汀的最大吸收波长及峰强度无明显变化，结果见图9、图12、图15和图16。
实施例7 氢溴酸沃替西汀:聚丙烯酸树脂IV＝1:1.5混合物制备
7a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:1.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀半盐5.00克、过100目粉末状聚丙烯酸树脂IV7.50克，置洁净干燥的100ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1:1.5的混合物粉末10.98克，得率87.84％，含量检测为35.71％(以沃替西汀计)。
取相当于20mg沃替西汀的1:1.5的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明刺激性明显减轻。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表18：
表18 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000028
7b)氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:1.5混合物制备
取过200目不锈钢筛的氢溴酸沃替西汀一盐5.00克、过100目粉末状聚丙烯酸树脂IV 7.50克，置洁净干燥的100ml螺口玻璃试剂瓶中，用Vortex-2型漩涡混匀仪混合5分钟，过100目不锈钢筛后继续用漩涡混匀仪混合5分钟，取出供检测样品0.50克，剩余物料收集后堆积在直径75mm不锈钢盘中，置DHG-9070A型热风循环烘箱，120-130℃加热30分钟，物料变为半流体状态，取出放冷后，用BJ-300A多功能粉碎机经过多次粉碎过100目不锈钢筛后，得到1:1.5的混合物粉末11.23克，得率89.84％，含量检测为31.12％(以沃替西汀计)。
取相当于20mg沃替西汀的1:1.5的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明刺激性明显减轻。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表19：
表19 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000029
紫外扫描图显示处理后的物料沃替西汀的最大吸收波长及峰强度无明显变化，结果见图8、图17、图18和图19。
实施例8 氢溴酸沃替西汀半盐:聚丙烯酸树脂＝1:0.3固体分散体制备
8a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:0.3固体分散体制备
取10.00克氢溴酸沃替西汀半盐、3.00克聚丙烯酸树脂IV、0.70克PEG4000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料10.29克，得率为75.11％，检测含量为62.97％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg 沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体有轻度刺激，能耐受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表20：
表20 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000030
8b)氢溴酸沃替西汀半盐:聚丙烯酸树脂II＝1:0.3固体分散体制备
取10.00克氢溴酸沃替西汀半盐、3.00克聚丙烯酸树脂II加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体有轻度刺激，能耐受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表21：
表21 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000031
Figure PCTCN2020113341-appb-000032
实施例9 氢溴酸沃替西汀:掩味辅料＝1:0.7固体分散体制备
9a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:0.7固体分散体制备
取10.00克氢溴酸沃替西汀半盐、7.70克聚丙烯酸树脂IV(其购自供应商罗姆公司的尤特奇E100或尤特奇E PO、广州茂丰药用辅料有限公司的尤释E或尤释E100)、安徽山河药用辅料有限公司的聚丙烯酸树脂IV(商品名))加入至170.00克药用乙醇中，加热至50-55℃搅拌溶解，50-55℃保温备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、物料进料温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料12.69克，得率为71.69％，检测含量为49.47％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀的固体分散体几乎无刺激。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表22：
表22 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000033
氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:0.7的固体分散体X射线粉末衍射图见图20，聚丙烯酸树脂IV喷雾干燥后X射线粉末衍射图为图21。
9a)中的固体分散体按2015版中华人民共和国药典要求进行了稳定性试验(6个月的加速，40±2℃，湿度75％±5％)，稳定性良好；9a)中的固体分散体在0.1N的盐酸及pH 4.5醋酸盐缓冲液中的溶出度(桨法，50转/分钟)溶出速度(10分钟数据)快、溶出完全(30 分钟)，结果见表23。
表23 氢溴酸沃替西汀一盐稳定性试验表
Figure PCTCN2020113341-appb-000034
9b)氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:0.77固体分散体制备
取10.00克氢溴酸沃替西汀一盐、7.70克聚丙烯酸树脂IV(其购自供应商罗姆公司的尤特奇E100或尤特奇E PO、广州茂丰药用辅料有限公司的尤释E或尤释E100)、安徽山河药用辅料有限公司的聚丙烯酸树脂IV(商品名))加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料11.73克，得率为66.27％，检测含量为44.47％(以沃替西汀计)，测得的固体分散体中氢溴酸沃替西汀的溴含量为11.83％。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀的固体分散体有轻微刺激。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表24：
表24 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000035
Figure PCTCN2020113341-appb-000036
氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:0.77的固体分散体X射线粉末衍射图见图22，聚丙烯酸树脂IV喷雾干燥后X射线粉末衍射图为图21。
9b)中的固体分散体按2015版中华人民共和国药典要求进行了稳定性试验(6个月的加速，40±2°0，湿度75％±5％)，稳定性良好；9b)中的固体分散体在0.1N的盐酸及pH 4.5醋酸盐缓冲液中的溶出度(桨法，50转/分钟)溶出速度(10分钟数据)快、溶出完全(30分钟)，结果见表25。
表25 氢溴酸沃替西汀一盐稳定性试验表
Figure PCTCN2020113341-appb-000037
9c)氢溴酸沃替西汀半盐:尤特奇RL100:PEG6000＝1:0.7:0.07固体分散体制备
取10.00克氢溴酸沃替西汀半盐、7.00克尤特奇RL100、0.70克PEG6000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀的固体分散体几乎无刺激。
自制样品：瞬时刺激++，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表26：
表26 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000038
Figure PCTCN2020113341-appb-000039
9d)氢溴酸沃替西汀半盐:尤特奇S100:PEG6000＝1:0.7固体分散体制备
取10.00克氢溴酸沃替西汀半盐、7.00克尤特奇S100加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀的固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表27：
表27 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000040
9e)氢溴酸沃替西汀半盐:尤特奇L100＝1:0.7固体分散体制备
取10.00克氢溴酸沃替西汀半盐、7.00克尤特奇L100加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀的固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表28：
表28 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000041
实施例10 氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:1固体分散体制备
取10.00克氢溴酸沃替西汀半盐、10.00克聚丙烯酸树脂IV、0.70克PEG6000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料13.31克，得率为64.30％，检测含量为43.38％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表29：
表29 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000042
Figure PCTCN2020113341-appb-000043
实施例11 氢溴酸沃替西汀:掩味辅料＝1:1.5固体分散体制备
11a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:1.5固体分散体制备
取10.00克氢溴酸沃替西汀半盐、15.00克聚丙烯酸树脂IV加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料18.11克，得率为72.44％，检测含量为34.47％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表30：
表30 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000044
11b)氢溴酸沃替西汀一盐:聚丙烯酸树脂IV＝1:1.5固体分散体制备
取10.00克氢溴酸沃替西汀一盐、15.00克聚丙烯酸树脂IV、0.70克PEG6000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、 蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料17.17克，得率为66.81％，检测含量为30.57％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表31：
表31 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000045
11c)氢溴酸沃替西汀一盐:乙基纤维素N10＝1:1.5固体分散体制备
取10.00克氢溴酸沃替西汀一盐、15.00克乙基纤维素N10加入至300.00克药用乙醇中，搅拌溶解，加入过200目筛的枸橼酸钾1.00克，搅拌分散均匀后持续搅拌防沉降，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的沃替西汀氢溴酸一盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表32：
表32 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000046
实施例12 氢溴酸沃替西汀半盐:掩味辅料＝1:2固体分散体制备
12a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:2固体分散体制备
取10.00克氢溴酸沃替西汀半盐、20.00克聚丙烯酸树脂IV、0.70克PEG6000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料20.20克，得率为65.80％，检测含量为27.99％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表33：
表33 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000047
Figure PCTCN2020113341-appb-000048
12b)氢溴酸沃替西汀半盐:醋酸纤维素＝1:2固体分散体制备
取10.00克氢溴酸沃替西汀半盐、20.00克醋酸纤维素、0.70克PEG8000加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的沃替西汀氢溴酸半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表34：
表34 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000049
实施例13 氢溴酸沃替西汀半盐+掩味辅料固体分散体制备
13a)氢溴酸沃替西汀半盐:聚丙烯酸树脂IV＝1:5固体分散体制备
取10.00克氢溴酸沃替西汀半盐、50.00克聚丙烯酸树脂IV加入至500.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，得物料49.29克，得率为82.15％，检测含量为14.67％(以沃替西汀计)。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表35：
表35 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000050
13b)氢溴酸沃替西汀半盐:羟丙纤维素LF＝1:3固体分散体制备
取10.00克沃替西汀氢溴酸半盐、30.00克羟丙纤维素LF及1克葡甲胺加入至300.00克药用乙醇中，搅拌溶解，备用。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于80目粉末，即得。
取相当于20mg沃替西汀的固体分散体，经5名受试者尝试口感，并与相当于20mg沃替西汀的沃替西汀氢溴酸半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体几乎无刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表36：
表36 沃替西汀氢溴酸半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000051
Figure PCTCN2020113341-appb-000052
实施例14 氢溴酸沃替西汀+聚丙烯酸树脂固体分散体制备
14a)氢溴酸沃替西汀半盐:聚丙烯酸树脂II＝1:5固体分散体制备
取10.00克氢溴酸沃替西汀半盐、50.00克聚丙烯酸树脂II，加乙醇至500.00克，水浴40-50℃搅拌溶解后，用0.45um微孔滤膜滤过，滤液在搅拌状态下用5％(g/g)氢氧化钠溶液调节物料酸碱度至物料中不再出现析出物后(此时pH为8.54)，用旋转蒸发器真空去除乙醇，得到的固形物用真空冷冻干燥机40-50℃除去残留乙醇后，研磨过100目不锈钢筛，得到含沃替西汀的固体分散体物50.54克，得率84.23％，检测含量为14.79％(以沃替西汀计)
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明感觉不到沃替西汀特有的刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表37：
表37 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000053
14b)氢溴酸沃替西汀一盐:聚丙烯酸树脂II＝1:1.5固体分散体制备
取10.00克氢溴酸沃替西汀一盐、15.00克聚丙烯酸树脂II，加乙醇至250.00克，水浴40-50℃搅拌溶解后，用0.45um微孔滤膜滤过，滤液在搅拌状态下用5％(g/g)氢氧化钠溶液调节物料酸碱度至物料中不再出现析出物后(此时pH为8.32)，用旋转蒸发器真空去除乙醇，得到的固形物用真空冷冻干燥机40-50℃除去残留乙醇后，研磨过100目不锈钢筛，得到含沃替西汀的固体分散体物19.67克，得率78.68％，检测含量为29.97％(以沃替西汀计)
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀一盐100目粉末进行对比，证明感觉不到沃替西汀特有的刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表38：
表38 氢溴酸沃替西汀一盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000054
氢溴酸沃替西汀一盐:聚丙烯酸树脂II＝1:1.5固体分散体X射线粉末衍射图见图23，聚丙烯酸树脂II(乙醇旋蒸)后X射线粉末衍射图为图24。
实施例15 氢溴酸沃替西汀半盐:聚丙烯酸树脂II＝1:1.5固体分散体制备
取10.00克氢溴酸沃替西汀半盐、15.00克聚丙烯酸树脂II，加乙醇至250.00克，水浴40-50℃搅拌溶解后，用0.45um微孔滤膜滤过，滤液在搅拌状态下用5％(g/g)氢氧化钠溶液调节物料酸碱度至物料中不再出现析出物后(此时pH为8.47)，分离出不溶物加入至纯化水400克中，于40-50℃匀浆过100目筛网后，用BWF-1G多功能流化床顶喷制粒，得到的粉末研磨过100目不锈钢筛，得到含沃替西汀的固体分散体12.94克，得率51.76％，检测含量为35.77％(以沃替西汀计)。
取相当于20mg沃替西汀的混合物粉末，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明感觉不到沃替西汀特有的刺激。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表39：
表39 氢溴酸沃替西汀半盐固体分散体口感对比测试
Figure PCTCN2020113341-appb-000055
Figure PCTCN2020113341-appb-000056
氢溴酸沃替西汀半盐:聚丙烯酸树脂II＝1:1.5固体分散体X射线粉末衍射图为图25，聚丙烯酸树脂II(乙醇旋蒸)X射线粉末衍射图见图24。
实施例16 掩味包衣粉末制备掩味颗粒
取尤特奇RS100 10.00克，加入150.00克乙醇中，搅拌溶解后备用。
取实施例1d粉末10.00克加入至上述溶液中，搅拌分散后过60目不锈钢筛网，持续搅拌防沉降。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度50-55℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于50目粉末，得粉末15.87克，得率79.35％，含量25.47％(以沃替西汀计)。
取相当于20mg沃替西汀的颗粒，经5名受试者尝试口感，并与相当于20mg沃替西汀的氢溴酸沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体有轻度刺激，能耐受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表40：
表40 氢溴酸沃替西汀半盐掩味包衣颗粒口感对比测试
Figure PCTCN2020113341-appb-000057
实施例17 固体分散体制备掩味包衣粉末
取壳聚糖(脱乙酰度大于等于85％)5.00克，加入100.00克纯化水中，搅拌分散后备 用。
取实施例9a粉末10.00克加入至上述溶液中，搅拌分散后过60目不锈钢筛网，持续搅拌防沉降。
按顶喷制粒模式安装的BWF-1G多功能流化床，设置风量33m 3、进风温度60-65℃、蠕动泵转速8rpm、雾化压力1.0-1.5atm，喷入上述步骤制备好溶液，随时观察物料状态，并适当调整参数，保证雾化及干燥正常，喷雾结束，持续30分钟后，停止加热，待物料温度降至室温后，收集物料，研磨筛分收集粒径小于60目粉末，得粉末11.11克，得率74.07％，含量35.17％(以沃替西汀计)。
取相当于20mg沃替西汀的粉末经5名受试者尝试口感，并与相当于20mg沃替西汀氢溴酸的沃替西汀半盐100目粉末进行对比，证明未处理物料刺激明显，几乎不能耐受，处理后的沃替西汀固体分散体有轻度刺激，能耐受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
对照品：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表41：
表41 氢溴酸沃替西汀半盐固体分散体掩味粉末口感对比测试
Figure PCTCN2020113341-appb-000058
实施例18 10mg/片氢溴酸沃替西汀一盐薄膜包衣片的制备
制成100片、每片片芯重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000059
制法：
(1)取处方量实施例9b制备的粉末、微晶维纤素、甘露醇P100SD、羧甲淀粉钠、硬脂酸镁置洁净干燥的50ml螺口玻璃试剂瓶中，用漩涡混匀仪混合五分钟后取出过80目筛后继续混合五分钟，取出过80目筛后继续混合五分钟即得压片预混料；
(2)取压片预料混用ZP8压片机，直径8mm模具，控制片重147-157mg/片压片，控制压片硬度40-60N，即得片芯；
(3)取胃溶性包衣材料，用纯化水制成含固量约10％的混悬液，持续搅拌备用；
(4)采用步骤(3)制备的包衣液，用高效包衣机对片芯进行包衣，即得，片芯实际增重约1％。
分别取市售品(10mg/片)及本申请的制成品研成粉末后经10名受试者尝试口感，市售品有明显刺激，受试者不能耐受，本申请的自制品口感可接受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
市售品：瞬时刺激+++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表42：
表42 氢溴酸沃替西汀一盐薄膜包衣片口感对比测试
Figure PCTCN2020113341-appb-000060
本申请的制成品按2015版中华人民共和国药典要求进行了初步稳定性试验，并与市售品同步对比，本申请的制成品在0.1N的盐酸及pH 4.5醋酸盐缓冲液中的溶出度(桨法，50转/分钟)溶出速度(10分钟数据)明显快于市售品、溶出程度(30分钟)明显优于市售品，结果见表43。
表43氢溴酸沃替西汀一盐初步稳定性试验表(温度50℃±2℃，湿度75％±5％)
Figure PCTCN2020113341-appb-000061
实施例19 20mg/片口腔崩解片的制备(压制片)
19a：用氢溴酸沃替西汀半盐制成100片、每片重0.088克的配方组成如下：
Figure PCTCN2020113341-appb-000062
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过100目筛后备用；
(2)分别称取处方量的氢溴酸沃替西汀半盐、无水磷酸三钠、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置50ml玻璃瓶制备中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预混料；
(3)分别取压片预混料用ZP8旋转压片机，直径6.0mm浅凹模具，控制片重86-90mg/片,硬度0.7-1.5kG压片即得。
19b：用氢溴酸沃替西汀一盐制成100片、每片重0.088克的配方组成如下：
Figure PCTCN2020113341-appb-000063
Figure PCTCN2020113341-appb-000064
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过100目筛后备用；
(2)分别称取处方量的氢溴酸沃替西汀一盐、无水磷酸三钠、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置50ml玻璃瓶制备中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预混料；
(3)分别取压片预混料用ZP8旋转压片机，直径6.0mm浅凹模具，控制片重86-90mg/片,硬度0.7-1.5kG压片即得。
经10名受试者尝试口感，两份样品均无沙砾感；用氢溴酸沃替西汀半盐制成的样品几乎感觉不到刺激，口感较好；用氢溴酸沃替西汀一盐制成的样品刺激明显强于氢溴酸沃替西汀半盐样品，有轻度的不适。
自制样品19a：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品19b：瞬时刺激++，延时刺激30分钟以上消失，苦涩感不可接受。
详见表44：
表44 氢溴酸沃替西汀半盐口腔崩解片口感测试
Figure PCTCN2020113341-appb-000065
Figure PCTCN2020113341-appb-000066
实施例20 20mg/片口腔崩解片的制备(压制片)：
氢溴酸沃替西汀半盐分散体制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000067
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过100目筛后备用；
(2)分别称取处方量的固体分散体、无水磷酸三钠、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置50ml玻璃制备瓶中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预混料；
(3)分别取压片预混料用ZP8旋转压片机，直径8.0mm浅凹模具，控制片重145-149mg/片,硬度15-30N压片即得。
酸碱度及相对暴露量检测值为：8.92，0.19％(7.5ug/ml)
经10名受试者尝试口感，样品在口腔10秒内溶散，无沙砾感、几乎感觉不到刺激，口感好。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表45：
表45 氢溴酸沃替西汀半盐固体分散体口腔崩解片口感测试
受试者 瞬时刺激 延时刺激(分钟) 苦涩感 沙砾感
受试者1 + 1-15 可接受 无
受试者2 + 1-15 可接受 无
受试者3 + 1-15 可接受 无
受试者4 + 1-15 可接受 无
受试者5 + 1-15 可接受 无
受试者6 + 1-15 可接受 无
受试者7 + 1-15 可接受 无
受试者8 + 1-15 可接受 无
受试者9 + 1-15 可接受 无
受试者10 ++ 1-15 可接受 无
实施例21 20mg/片口腔崩解片的制备(冻干片)
处方：
Figure PCTCN2020113341-appb-000068
纯化水加至16克，制成40片,每片约0.4克，含固形物约0.1548克。
制法：
(1)氢溴酸沃替西汀氢半盐、红氧化铁过100目筛后备用；
(2)称取处方量甘露醇、山梨醇、PEG4000、药用B型明胶、纽甜等物料置洁净干燥的20ml管制螺口玻璃瓶中，加纯化水约8克，拧紧瓶盖，在50℃振荡溶解后，放冷至室温，加处方量的氢溴酸沃替西汀半盐、红氧化铁、无水磷酸三钠，振荡分散后加纯化水至处放量，振荡分散后过80目不锈钢筛网3次，即得分装用混悬液，持续搅拌防止沉降；
(3)分装用混悬液按每孔0.4克分装于模孔中，冷冻干燥；
(4)将冷冻干燥后的样品热封，即得冻干口腔崩解片。
酸碱度及相对暴露量检测值为：10.42，0.27％(10.7ug/ml)
经10名志愿受试者测试，样品在口腔中5秒内崩解，无沙砾感、刺激极轻微。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表46：
表46 氢溴酸沃替西汀半盐口腔崩解片口感测试
受试者 瞬时刺激 延时刺激(分钟) 苦涩感 沙砾感
受试者1 + 1-15 可接受 无
受试者2 + 1-15 可接受 无
受试者3 ++ 1-15 可接受 无
受试者4 + 1-15 可接受 无
受试者5 + 1-15 可接受 无
受试者6 + 1-15 可接受 无
受试者7 + 1-15 可接受 无
受试者8 ++ 1-15 可接受 无
受试者9 + 1-15 可接受 无
受试者10 + 1-15 可接受 无
实施例22 20mg/片口腔崩解片的制备(压制片、冻干片)
22a：氢溴酸沃替西汀半盐微粉包衣粉末制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000069
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过80目筛后备用；
(2)分别称取处方量的实施例3a制备的粉末、碳酸氢钠、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置20ml管制螺口玻璃瓶中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预 混料；
(3)分别取压片预混料用ZP8旋转压片机，直径8.0mm浅凹模具，控制片重145-149mg/片，硬度15-30N压片即得。
22b：氢溴酸沃替西汀半盐微粉包衣粉末制成冻干型口崩片
处方：
Figure PCTCN2020113341-appb-000070
纯化水加至16克，制成40片,每片约0.4克，含固形物约0.1799克
制法：
(1)原料药过100目筛后备用；
(2)称取处方量甘露醇、山梨醇、PEG4000、药用B型明胶、纽甜等物料置洁净干燥的20ml管制螺口玻璃瓶中，加纯化水约8克，拧紧瓶盖，在50℃振荡溶解后，放冷至室温，加处方量的实施例3a制备的粉末、碳酸氢钠，振荡分散后加纯化水至处方量，振荡分散后过80目不锈钢筛网3次，即得分装用混悬液，持续搅拌防止沉降；
(3)分装用混悬液按每孔0.4克分装于模孔中，冷冻干燥；
(4)将冷冻干燥后的样品热封，即得冻干口腔崩解片。
酸碱度及相对暴露量检测值为：
样品22a：pH 8.02，0.21％(8.3ug/ml)
样品22b：pH 9.79，0.25％(9.9ug/ml)
经10名志愿受试者测试，样品22a在口腔中10秒内崩解、样品20b在口腔中5秒内崩解，均无沙砾感、刺激极轻微。
自制样品22a：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品22b：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表47：
表47 氢溴酸沃替西汀半盐微粉包衣口腔崩解片口感比对
Figure PCTCN2020113341-appb-000071
Figure PCTCN2020113341-appb-000072
实施例23 20mg/片口腔崩解片的制备(压制片、冻干片)
23a：氢溴酸沃替西汀半盐微粉包衣粉末制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000073
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过80目筛后备用；
(2)分别称取处方量实施例7a制备的粉末、无水磷酸三钾、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置50ml玻璃制备瓶中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预混料；
(3)分别取压片预混料用ZP8旋转压片机，直径8.0mm浅凹模具，控制片重145-149mg/片,硬度15-30N压片即得。
23b：氢溴酸沃替西汀半盐微粉包衣粉末制成冻干型口崩片
处方：
Figure PCTCN2020113341-appb-000074
纯化水加至16克，制成40片,每片约0.4克，含固形物约0.1881克
制法：
(1)原料药过100目筛后备用；
(2)称取处方量甘露醇、山梨醇、PEG4000、药用B型明胶、纽甜等物料置洁净干燥的20ml管制螺口玻璃瓶中，加纯化水约8克，拧紧瓶盖，在50℃振荡溶解后，放冷至室温，加处方量的实施例7制备的粉末、无水磷酸三钾、红氧化铁，振荡分散后加纯化水至处方量，振荡分散后过100目不锈钢筛网3次，即得分装用混悬液，持续搅拌防止沉降；
(3)分装用混悬液按每孔0.4克分装于模孔中，冷冻干燥；
(4)将冷冻干燥后的样品热封，即得冻干口腔崩解片。
酸碱度及相对暴露量检测值为：
样品23a：pH 8.02，0.21％(8.3ug/ml)
样品23b：pH 9.79，0.25％(9.9ug/ml)
经10名志愿受试者测试，样品21a在口腔中10秒内崩解、样品21b在口腔中5秒内崩解，均无沙砾感、刺激极轻微。
自制样品23a：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品23b：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表48：
表48 氢溴酸沃替西汀半盐固体分散体口腔崩解片口感比对
Figure PCTCN2020113341-appb-000075
Figure PCTCN2020113341-appb-000076
实施例24 20mg/片口腔崩解片的制备(压制片、冻干片)
24a：氢溴酸沃替西汀半盐固体分散体粉末制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000077
制法：
(1)纽甜、红氧化铁过200目，其它原辅料过80目筛后备用；
(2)分别称取处方量的实施例11a制备的粉末、无水磷酸氢二钠、甘露醇P100SD、交联聚维酮XL、交联羧甲纤维素钠、羧甲淀粉钠、硬脂酸镁、纽甜、红氧化铁等物料置50ml玻璃制备瓶中，拧紧瓶盖，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛，用漩涡混匀仪混合五分钟后取出过80目不锈钢筛后，用漩涡混匀仪混合五分钟混匀即得压片预混料；
(3)分别取压片预混料用ZP8旋转压片机，直径8.0mm浅凹模具，控制片重147-157mg/片,硬度15-30N压片即得。
24b：氢溴酸沃替西汀半盐固体分散体粉末制成冻干型口崩片
处方：
Figure PCTCN2020113341-appb-000078
纯化水加至16克，制成40片,每片约0.4克，含固形物约0.1901克
制法：
(1)红氧化铁过200目后备用。
(2)称取处方量甘露醇、山梨醇、PEG4000、药用B型明胶、纽甜等物料置洁净干燥的20ml管制螺口玻璃瓶中，加纯化水约8克，拧紧瓶盖，在50℃振荡溶解后，放冷至室温，加处方量的实施例11a制备的粉末、无水磷酸二钠、红氧化铁，振荡分散后加纯化水至处方量，振荡分散后过80目不锈钢筛网3次，即得分装用混悬液，持续搅拌防止沉降；
(3)分装用混悬液按每孔0.4克分装于模孔中，冷冻干燥；
(4)将冷冻干燥后的样品热封，即得冻干口腔崩解片。
酸碱度及相对暴露量检测值为：
样品24a：pH 7.98，0.29％(11.5ug/ml)
样品24b：pH 9.79，0.35％(13.9ug/ml)
经10名志愿受试者测试，样品22a在口腔中10秒内崩解、样品22b在口腔中5秒内崩解，均无沙砾感、刺激极轻微。
自制样品24a：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
自制样品24b：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表49：
表49 氢溴酸沃替西汀半盐固体分散体口腔崩解片口感比对
Figure PCTCN2020113341-appb-000079
Figure PCTCN2020113341-appb-000080
实施例25 20mg/片分散片的制备
制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000081
制法：
(1)取处方量实施例10制备的固体分散体粉末、微晶维纤素、甘露醇P100SD、氢氧化钙、羧甲淀粉钠、纽甜、硬脂酸镁置洁净干燥的50ml螺口玻璃试剂瓶中，用漩涡混匀仪混合五分钟后取出过80目筛，用漩涡混匀仪混合五分钟后取出过80目筛后继续混合五分钟即得压片预混料；
(2)取压片预料混用ZP8旋转压片机，直径8.0mm浅凹模具压片，控制片重147-157mg/片压片，控制压片硬度50-80N，即得。
酸碱度及相对暴露量检测值为：pH 8.79，0.45％(17.9ug/ml)
样品研成粉末后，取相当于沃替西汀20mg的粉末经10名受试者尝试口感，1分钟内刺激轻微，制成品口感可接受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表50：
表50 氢溴酸沃替西汀半盐固体分散体分散片口感测试
受试者 瞬时刺激 延时刺激(分钟) 苦涩感 沙砾感
受试者1 + 1-15 可接受 无
受试者2 + 1-15 可接受 无
受试者3 + 1-15 可接受 无
受试者4 ++ 1-15 可接受 无
受试者5 + 1-15 可接受 无
受试者6 + 1-15 可接受 无
受试者7 ++ 1-15 可接受 无
受试者8 + 1-15 可接受 无
受试者9 + 1-15 可接受 无
受试者10 + 1-15 可接受 无
实施例26 20mg/片分散片的制备
制成100片、每片重0.152克的配方组成如下：
Figure PCTCN2020113341-appb-000082
制法：
(1)取处方量实施例16制备的掩味包衣粉末、微晶维纤素、甘露醇P100SD、羧甲淀粉钠、纽甜、硬脂酸镁置洁净干燥的50ml螺口玻璃试剂瓶中，用漩涡混匀仪混合五分钟后取出过80目筛，用漩涡混匀仪混合五分钟后取出过80目筛后继续混合五分钟即得压片预混料；
(2)取压片预料混用ZP8旋转压片机，直径8.0mm浅凹模具压片，控制片重147-157mg/片压片，控制压片硬度50-80N，即得。
酸碱度及相对暴露量检测值为：pH 8.79，0.45％(17.9ug/ml)
样品研成粉末后，取相当于沃替西汀20mg的粉末经10名受试者尝试口感，1分钟内刺激轻微，制成品口感可接受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表51：
表51 沃替西汀氢溴酸半盐分散片口感测试
受试者 瞬时刺激 延时刺激(分钟) 苦涩感 沙砾感
受试者1 + 1-15 可接受 无
受试者2 + 1-15 可接受 无
受试者3 + 1-15 可接受 无
受试者4 + 1-15 可接受 无
受试者5 + 1-15 可接受 无
受试者6 + 1-15 可接受 无
受试者7 + 1-15 可接受 无
受试者8 + 1-15 可接受 无
受试者9 + 1-15 可接受 无
受试者10 + 1-15 可接受 无
实施例27 颗粒剂的制备或干混悬剂(每袋5克，含沃替西汀20mg)
制成100袋、每袋重5克的配方组成如下：
Figure PCTCN2020113341-appb-000083
制法：
(1)原辅料过100目筛后备用；
(2)取处方量氢溴酸沃替西汀半盐、木糖醇、甘露醇P100SD、微晶维纤素、胶态二氧化硅、羧甲纤维素钠、枸橼酸三钾、羧甲淀粉钠、纽甜及硬脂酸镁置2升不锈钢料斗中，把料斗安装在料斗混合机上，10转/分钟混合10分钟后取出，用旋转整粒机、0.5mm不锈钢圆孔网板整粒后，继续用料斗混合机10转/分钟混合10分钟，即得制粒用预混料；
(3)取制粒用预混料用干法制粒机压成薄片，用1.5mm不锈钢圆孔网板整粒，用40目不锈钢筛网筛分后，细粉返回重新制粒。得颗粒461.34克，得率92.2％；
(4)制得的颗粒按5克/袋装入铝塑热封袋后，热封即得。
分别取样品一袋，分散到20ml纯化水中，经10名受试者尝试口感，制成品口感可接受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表52：
表52 氢溴酸沃替西汀半盐颗粒剂口感测试
Figure PCTCN2020113341-appb-000084
实施例28 口服混悬剂的制备(每瓶5ml，含沃替西汀20mg)
氢溴酸沃替西汀半盐固体分散体制备5ml；20mg口服混悬液100支处方如下：
Figure PCTCN2020113341-appb-000085
纯化水加至500ml，
制法：
(1)取处方量实施例13a固体分散体、木糖醇、羧甲纤维素钠、乙酸钠加入纯化水400ml中，12000转/分钟匀浆2分钟，持续搅拌备用；
(2)上述步骤制得的混悬液过100目不锈钢筛后用1N的盐酸或1N的氢氧化钠溶液调节pH值至8.0-8.5后，加纯化水至处方量，搅拌备用；
(3)按每支5ml将混悬液分装至管制西林瓶中，加塞，轧盖即得。
分别取样品5ml，经10名受试者尝试口感，制成品口感可接受。
自制样品：瞬时刺激+，延时刺激1-15分钟内消失，苦涩感可接受。
详见表53：
表53：氢溴酸沃替西汀半盐固体分散体口服混悬剂口感测试
Figure PCTCN2020113341-appb-000086
对比实施例1不同盐的口感对比
分别将相当于5mg沃替西汀的乳酸沃替西汀盐、氢溴酸沃替西汀一盐和氢溴酸沃替西汀半盐过100目的粉末直接放在舌面前上部一分钟，每个盐型组有10名受试者，每个受试者每种盐型随机尝试3次，尝试完一种盐型的口感后，漱口，待完全无刺激后再尝试另外一种盐型。尝试口感后记录苦味级别和舌部刺激感，数秒后吐出，漱口，记录刺激性消退时间，1-1.5小时后进食，再次记录刺激感。下表54为10名受试者30次尝试对不同沃替西汀的盐型口感对比。
表54 10名受试者30次尝试对不同沃替西汀的盐型口感对比(单位：次)
Figure PCTCN2020113341-appb-000087
注：(1)由于刺激性太强，几乎无法忍受，多次漱口也无法消退，消退时间均高于1小时，进食后刺激感也无法消退。
(2)漱口后完全无刺激。
对比实施例2本申请的固体分散体与上市制剂口感对比
取由实施例9b制备的相当于10mg沃替西汀的固体分散体、相当于10mg沃替西汀的氢溴酸沃替西汀半盐粉末和相当于10mg沃替西汀的氢溴酸沃替西汀一盐上市片剂压制成的粉末，过100目筛后，3种粉末直接放在舌面前上部一分钟，每种粉末组有20名受试者，尝试完一种粉末的口感后，漱口，待完全无刺激后再尝试另外一种。尝试口感后记录苦味级别和舌部刺激感，数秒后吐出，漱口，记录刺激性消退时间，1-1.5小时后进食，再次记录刺激感。下表55为20名受试者对不同沃替西汀的粉末口感对比。
表55 20名受试者对不同沃替西汀粉末的口感对比(单位：个)
Figure PCTCN2020113341-appb-000088
注：(1)由于刺激性太强，几乎无法忍受，多次漱口也无法消退，消退时间均高于2小时，进食后刺激感也无法消退。
(2)漱口后完全无刺激。

Claims (34)

  1. 氢溴酸沃替西汀半盐的口腔分散制剂，其包含氢溴酸沃替西汀半盐和药物可接受的辅料。
  2. 如权利要求1所述的口腔分散制剂，其为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂，优选地所述片剂为口崩片或分散片，更优选地为口崩片。
  3. 氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂，其包含氢溴酸沃替西汀半盐或一盐以及药物可接受的掩味辅料。
  4. 如权利要求3所述的口腔分散掩味制剂，其中所述氢溴酸沃替西汀半盐或一盐被所述掩味辅料包衣，形成包衣颗粒；优选地，所述掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、或聚乙烯醇；任选地，所述掩味辅料中包含碱性辅料；任选地，所述包衣颗粒中包含抗粘剂。
  5. 如权利要求3所述的口腔分散掩味制剂，其中所述氢溴酸沃替西汀半盐或一盐分散在掩味辅料中，形成固体分散体；优选地，所述掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类；任选地，所述掩味辅料中包含碱性辅料。
  6. 如权利要求3所述的口腔分散掩味制剂，其中所述氢溴酸沃替西汀半盐或一盐与碱性辅料混合，优选与磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺中的至少一种混合，形成组合物。
  7. 氢溴酸沃替西汀半盐或一盐的掩味包衣颗粒，其中所述掩味包衣辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、或聚乙烯醇类；任选地，所述掩味包衣辅料中包含碱性辅料；任选地，所述掩味包衣辅料中包含抗粘剂。
  8. 氢溴酸沃替西汀半盐或一盐的掩味固体分散体，其中掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类；任选地，所述掩味辅料中包含碱性辅料。
  9. 氢溴酸沃替西汀半盐或一盐的掩味组合物，其包含氢溴酸沃替西汀半盐或一盐以及碱性辅料；优选地，所述碱性辅料为磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺中的至少一种。
  10. 如权利要求4或5所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、或权利要求8所述的掩味固体分散体，其中所述甲基丙烯酸共聚物类为聚丙烯酸树脂，优选地聚丙烯酸树脂为聚丙烯酸树脂II或聚丙烯酸树脂IV。
  11. 如权利要求4所述的口腔分散掩味制剂或权利要求7所述的掩味包衣颗粒，其中所述氢溴酸沃替西汀半盐或一盐被所述掩味辅料包衣而形成包衣颗粒，所述包衣颗粒进一步分散在掩味辅料中而形成固体分散体；任选地，所形成的固体分散体进一步与碱性辅料混合。
  12. 如权利要求5所述的口腔分散掩味制剂或权利要求8所述的固体分散体，其中所述氢溴酸沃替西汀半盐或一盐分散在掩味辅料中而形成固体分散体，所述固体分散体进一步被掩味辅料包衣而形成包衣颗粒；任选地，所形成的包衣颗粒进一步与碱性辅料混合。
  13. 如权利要求4所述的口腔分散掩味制剂或权利要求7所述的掩味包衣颗粒，其中所述氢溴酸沃替西汀半盐或一盐被所述掩味辅料包衣而形成包衣颗粒，所述包衣颗粒进一步与碱性辅料混合。
  14. 如权利要求5所述的口腔分散掩味制剂或权利要求8所述的固体分散体，其中所述氢溴酸沃替西汀半盐或一盐分散在掩味辅料中而形成固体分散体，所述固体分散体进一步与碱性辅料混合。
  15. 如权利要求3所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、权利要求8所述的掩味固体分散体、或权利要求9所述的掩味组合物，其中所述氢溴酸沃替西汀半盐或一盐与药物可接受的掩味辅料的重量比为1:0.1-1:5，优选地1:0.3-1:3，更优选地1:0.5-1:1.5；其中所述氢溴酸沃替西汀半盐或一盐与所述药物可接受的碱性辅料的重量比1:0.01-1:1.1，优选地1:0.03-1:1。
  16. 如权利要求3所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、权利要求8所述的掩味固体分散体、或权利要求9所述的掩味组合物，其为晶态或非晶态物质。
  17. 如权利要求3所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、权利要求8所述的掩味固体分散体、权利要求9所述的掩味组合物、或权利要求15所述的口腔分散掩味制剂，其还包含填充剂、矫味剂、释放调节剂、增塑剂、抗粘剂、和/或崩解剂；优选地，该抗粘剂为滑石粉，占所述掩味包衣颗粒总重量的5％-25％，例如10％-20％；所述崩解剂为羧甲淀粉钠、交联羧甲纤维素钠、交联聚维酮及其组合，其占所述口腔分散掩味制剂总重量的1％-8％，优选地2％-6％；优选地所述矫味剂为纽甜，其占所述口腔分散掩味制剂总重量的0.05％-0.5％，优选地0.1％-0.3％。
  18. 如权利要求3所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、权利要求8所述的掩味固体分散体、或权利要求9所述的掩味组合物，其为或被制备为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂，优选地所述片剂为口崩片或分散片，更优选地为口崩片。
  19. 如权利要求1或2所述的口腔分散制剂、权利要求3所述的口腔分散掩味制剂、权利要求7所述的掩味包衣颗粒、权利要求8所述的掩味固体分散体、或权利要求9所述的掩味组合物，其中所述氢溴酸沃替西汀半盐或一盐为无定型物或晶体。
  20. 氢溴酸沃替西汀半盐在制备口腔分散剂、掩味包衣颗粒、掩味固体分散体、掩味组合物、或口腔分散掩味制剂中的用途，优选地所述制备口腔分散剂或者口腔分散掩味制剂为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂，优选地所述片剂为口崩片或分散片，更优选地为口崩片。
  21. 氢溴酸沃替西汀一盐在制备口腔分散剂、掩味包衣颗粒、掩味固体分散体、掩味组合物、或口腔分散掩味制剂中的用途，优选地所述制备口腔分散剂或者口腔分散掩味制剂为片剂、颗粒剂、胶囊剂、散剂、混悬剂、干混悬剂、溶液剂，优选地所述片剂为口崩片或分散片，更优选地为口崩片。
  22. 制备氢溴酸沃替西汀半盐或一盐的掩味包衣颗粒或其制剂的方法，其包括：
    (1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；优选地在粉碎后过20-300目筛，更优选地过100-200目筛；
    (2a)将掩味辅料在溶剂中分散，通过流化床将所述氢溴酸沃替西汀半盐或一盐粉末用所述掩味辅料包衣并去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀半盐或一盐；优选地，将掩味辅料和释放调节剂在溶剂中分散；更优选地，所述释放调节剂为聚乙二醇或碱性辅料；优选地，所述溶剂为水、乙醇或二氯甲烷；或者
    (2b)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料加入溶剂形成混悬液，通过流化床、喷雾干燥或蒸发去除溶剂后得到掩味辅料包衣的氢溴酸沃替西汀半盐或一盐；优选地，所述氢溴酸沃替西汀半盐或一盐粉末、掩味辅料、释放调节剂和/或增塑剂加入溶剂形成氢溴酸沃替西汀半盐或一盐的混悬液；优选地，所述增塑剂为聚乙二醇或枸橼酸三乙酯；优选地，所述溶剂为水、乙醇或二氯甲烷；
    (3)任选地，将所述包衣的氢溴酸沃替西汀半盐或一盐制备为制剂。
  23. 制备氢溴酸沃替西汀半盐或一盐的固体分散体或其制剂的方法，其包括：
    (1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；优选地在粉碎后过20-300目筛，更优选地过100-200目筛；
    (2a)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料混合，在50-150℃下加热软化或液化，降温固化，粉碎后得到粉末；优选地，将所述氢溴酸沃替西汀半盐或一盐粉末、掩味辅料和释放调节剂混合；或
    (2b)将所述氢溴酸沃替西汀半盐或一盐粉末和掩味辅料在溶剂中溶解，通过蒸馏、流化床或喷雾干燥去除溶剂，得到粉末；优选地，所述溶剂为水、乙醇或二氯甲烷；
    (3)任选地，将步骤(2a)或(2b)中得到的粉末制备为制剂。
  24. 如权利要求22或23所述的方法，其中所述掩味辅料为醋酸纤维素类、乙基纤维素类、羟丙基纤维素类、甲基丙烯酸共聚物类、壳聚糖类、共聚维酮、聚维酮、聚乙烯醇、或聚乙二醇类；优选地，所述甲基丙烯酸共聚物类为聚丙烯酸树脂；更优选地聚丙烯酸树脂为聚丙烯酸树脂II或聚丙烯酸树脂IV。
  25. 制备氢溴酸沃替西汀半盐或一盐的掩味组合物或其制剂的方法，其包括：
    (1)将氢溴酸沃替西汀半盐或一盐粉碎得到氢溴酸沃替西汀半盐或一盐粉末；优选地，粉碎后过50-300目筛，更优选地过100-200目筛；
    (2)将所述氢溴酸沃替西汀半盐或一盐粉末与碱性辅料混合得到掩味组合物；优选地，所述碱性辅料为磷酸三钠、磷酸氢二钠、磷酸氢二钾、碳酸钾、碳酸钠、碳酸氢钠、枸橼酸钾、乙酸钠、氢氧化钙、氢氧化钠、氢氧化钾、或葡甲胺；
    (3)任选地，将所述掩味组合物制备为制剂。
  26. 如权利要求22-25中任一项所述的方法，其中所述氢溴酸沃替西汀半盐或一盐与药物可接受的用于形成包衣或固体分散体的掩味辅料的重量比为1:0.1-1:5，优选地1:0.3-1:3，更优选地1:0.5-1:1.5；其中氢溴酸沃替西汀半盐或一盐与药物可接受的碱性辅料的重量比1:0.01-1:1.1，优选地1:0.01-1:1。
  27. 包含氢溴酸沃替西汀半盐和聚丙烯酸树脂IV的固体分散体，其中所述氢溴酸沃替西汀半盐与聚丙烯酸树脂IV的重量比为1:0.1-1:5，优选地1:0.3-1:2，更优选地1:0.5-1:1.5；优选地，具有图20所示的特征峰。
  28. 氢溴酸沃替西汀一盐和聚丙烯酸树脂IV形成的固体分散体，其中所述氢溴酸沃替西汀一盐与聚丙烯酸树脂IV的重量比为1:0.1-1:5，优选地1:0.3-1:2，更优选地1:0.5-1:1.5；优选地，具有图22所示的特征峰。
  29. 如权利要求27或28所述的固体分散体，其中使用Cu-Kα辐射，以2θ角度表示的X-射线粉末衍射图在以下位置具有特征峰：4.2±0.2°、14.5±0.2°、17.4±0.2°、19.2±0.2°、和22.6±0.2°。
  30. 如权利要求27或28所述的固体分散体，其中使用Cu-Kα辐射，以2θ角度表示的X-射线粉末衍射图在以下位置具有特征峰：4.2±0.2°、14.5±0.2°、16.6±0.2°、17.4±0.2°、19.2±0.2°、21.5±0.2°、22.6±0.2°、24.4±0.2°、26.0±0.2°、28.2±0.2°、和29.0±0.2°。
  31. 如权利要求27或28所述的固体分散体，其还包含PEG 4000、PEG 6000、PEG 8000中的至少一种；优选地，所述聚丙烯酸树脂IV与PEG 4000、PEG 6000、PEG 8000中的至少一种的重量比为1:0.05-1:2。
  32. 前述权利要求中任一项所述的氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物在制备抗抑郁药物中的用途。
  33. 前述权利要求中任一项所述的氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物，其用于治疗抑郁症或制备抗抑郁药物。
  34. 治疗抑郁症的方法，其包括向有此需要的对象施用前述权利要求中任一项所述的 氢溴酸沃替西汀半盐或一盐的口腔分散掩味制剂、掩味包衣颗粒、掩味固体分散体、掩味组合物。
PCT/CN2020/113341 2019-09-04 2020-09-03 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂 WO2021043227A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2020343816A AU2020343816A1 (en) 2019-09-04 2020-09-03 Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
JP2022502045A JP2022540249A (ja) 2019-09-04 2020-09-03 ボルチオキセチン臭化水素酸塩を含む口腔内味マスキング用コーティング顆粒、固体分散体及び製剤
BR112022002122A BR112022002122A2 (pt) 2019-09-04 2020-09-03 Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo
MX2022002444A MX2022002444A (es) 2019-09-04 2020-09-03 Granulo recubierto, dispersion solida y preparacion que contiene hidrobromuro de vortioxetina enmascarante de sabor oral.
EP20861501.3A EP4026539A4 (en) 2019-09-04 2020-09-03 COATED GRANULES, SOLID DISPERSION AND PREPARATION WITH VORTIOXETIN HYDROBROMIDE FOR ORAL TASTE MASK
KR1020227004281A KR20220061952A (ko) 2019-09-04 2020-09-03 구강 미각 차폐용 보티옥세틴 하이드로브로마이드 함유 코팅 과립, 고체분산체 및 제제
CA3146024A CA3146024A1 (en) 2019-09-04 2020-09-03 Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
US17/617,805 US20220249466A1 (en) 2019-09-04 2020-09-03 Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
ZA2022/00542A ZA202200542B (en) 2019-09-04 2022-01-11 Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
JP2023063529A JP2023089096A (ja) 2019-09-04 2023-04-10 ボルチオキセチン臭化水素酸塩を含む口腔内味マスキング用コーティング顆粒、固体分散体及び製剤
JP2023180274A JP2024010032A (ja) 2019-09-04 2023-10-19 ボルチオキセチン臭化水素酸塩を含む口腔内味マスキング用コーティング顆粒、固体分散体及び製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910571194.3 2019-09-04
CN201910571194 2019-09-04

Publications (1)

Publication Number Publication Date
WO2021043227A1 true WO2021043227A1 (zh) 2021-03-11

Family

ID=74736746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/113341 WO2021043227A1 (zh) 2019-09-04 2020-09-03 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂

Country Status (11)

Country Link
US (1) US20220249466A1 (zh)
EP (1) EP4026539A4 (zh)
JP (3) JP2022540249A (zh)
KR (1) KR20220061952A (zh)
CN (3) CN114796222B (zh)
AU (1) AU2020343816A1 (zh)
BR (1) BR112022002122A2 (zh)
CA (1) CA3146024A1 (zh)
MX (1) MX2022002444A (zh)
WO (1) WO2021043227A1 (zh)
ZA (1) ZA202200542B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113520998A (zh) * 2021-07-26 2021-10-22 北京丰科睿泰医药科技有限公司 一种伏硫西汀口服滴剂及其制备方法
CN116650488A (zh) * 2022-06-27 2023-08-29 中国人民解放军军事科学院军事医学研究院 一种氢溴酸伏硫西汀树脂复合物及其制备方法和其应用
GB2622880A (en) * 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
CN115869290B (zh) * 2022-12-07 2024-05-28 杭州成邦医药科技有限公司 一种西替利嗪口腔膜剂及其制备方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1525852A (zh) * 2001-03-09 2004-09-01 ������ҩ��ҵ���޹�˾ 被掩味的包衣颗粒和粒状物
WO2007144005A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CN103989650A (zh) * 2014-06-13 2014-08-20 李雪梅 一种口腔崩解药物组合物及其制备方法
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
WO2015044963A1 (en) * 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
CN106491604A (zh) * 2015-09-07 2017-03-15 常州方楠医药技术有限公司 一种无定型沃替西汀或其盐与药用辅料的组合物及其制备方法
EP3184104A1 (en) * 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
CN107412183A (zh) * 2017-04-17 2017-12-01 深圳市泛谷药业股份有限公司 一种氢溴酸沃替西汀片及其制备方法
CN107638425A (zh) * 2016-07-21 2018-01-30 常州爱诺新睿医药技术有限公司 一种新的含无定型沃替西汀氢溴酸盐的药用组合物及其制备方法
WO2018065348A1 (en) * 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
CN108498459A (zh) * 2017-02-23 2018-09-07 北京阜康仁生物制药科技有限公司 一种包含氢溴酸沃替西汀的药物组合物及其制备方法
CN109589314A (zh) * 2017-10-01 2019-04-09 万全万特制药（厦门）有限公司 含有氢溴酸沃替西汀口崩片的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608333A1 (en) * 2003-04-02 2005-12-28 Pliva Istrazivanje i Razvoj d.o.o. Pharmaceutical compositions having reduced bitter taste
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CN105030713A (zh) * 2015-06-27 2015-11-11 万特制药(海南)有限公司 一种沃替西汀缓释片及其制备方法
CN105111167A (zh) * 2015-08-06 2015-12-02 华南理工大学 一种沃替西汀半盐酸盐及其制备方法和药物组合物
RU2745617C2 (ru) * 2016-03-14 2021-03-29 Сантен Фармасьютикал Ко., Лтд. Антисептическое средство, включающее меглюмин или его соль
CN108069925A (zh) * 2016-11-16 2018-05-25 浙江京新药业股份有限公司 沃替西汀氢溴酸盐无水晶型i及其制备方法和应用

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1525852A (zh) * 2001-03-09 2004-09-01 ������ҩ��ҵ���޹�˾ 被掩味的包衣颗粒和粒状物
WO2007144005A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
US9562024B2 (en) 2013-09-12 2017-02-07 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
WO2015044963A1 (en) * 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
CN103989650A (zh) * 2014-06-13 2014-08-20 李雪梅 一种口腔崩解药物组合物及其制备方法
CN106491604A (zh) * 2015-09-07 2017-03-15 常州方楠医药技术有限公司 一种无定型沃替西汀或其盐与药用辅料的组合物及其制备方法
EP3184104A1 (en) * 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
CN107638425A (zh) * 2016-07-21 2018-01-30 常州爱诺新睿医药技术有限公司 一种新的含无定型沃替西汀氢溴酸盐的药用组合物及其制备方法
WO2018065348A1 (en) * 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
CN108498459A (zh) * 2017-02-23 2018-09-07 北京阜康仁生物制药科技有限公司 一种包含氢溴酸沃替西汀的药物组合物及其制备方法
CN107412183A (zh) * 2017-04-17 2017-12-01 深圳市泛谷药业股份有限公司 一种氢溴酸沃替西汀片及其制备方法
CN109589314A (zh) * 2017-10-01 2019-04-09 万全万特制药（厦门）有限公司 含有氢溴酸沃替西汀口崩片的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Pharmacopoeia of the People's Republic of China", 2015
GE HONG : "New Clinical Pharmacology", 31 March 2018, CHINA TRADITIONAL CHINESE MEDICINE PRESS, CN, ISBN: 978-7-5578-2500-3, article GE, HONG ET AL.: "Common Flavor Technology", pages: 1 - 3, XP009526538 *

Also Published As

Publication number Publication date
CA3146024A1 (en) 2021-03-11
US20220249466A1 (en) 2022-08-11
JP2023089096A (ja) 2023-06-27
CN114796222B (zh) 2024-03-29
EP4026539A1 (en) 2022-07-13
JP2022540249A (ja) 2022-09-14
ZA202200542B (en) 2023-11-29
CN112438979B (zh) 2022-05-27
CN114796222A (zh) 2022-07-29
BR112022002122A2 (pt) 2022-04-19
KR20220061952A (ko) 2022-05-13
JP2024010032A (ja) 2024-01-23
AU2020343816A1 (en) 2022-02-24
MX2022002444A (es) 2022-03-22
EP4026539A4 (en) 2023-07-19
CN114931579A (zh) 2022-08-23
CN112438979A (zh) 2021-03-05

Similar Documents

Publication Publication Date Title
WO2021043227A1 (zh) 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂
CA2631233C (en) Ganaxolone formulations and methods for the making and use thereof
TW590778B (en) Pharmaceutical composition of topiramate
AU2016400468B2 (en) Pharmaceutical preparation of palbociclib and preparation method thereof
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
TW201000472A (en) New solid pharmaceutical formulations comprising BIBW 2992
US10894049B2 (en) Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI788557B (zh) 穩定性優異的固態製劑
AU2012208319B2 (en) Solid molecular dispersion
WO2012036078A1 (ja) 不快な味が遮蔽された薬物含有膜被覆粒子
CN103417483B (zh) 盐酸美金刚缓释干混悬剂及其制备方法
JPWO2019208540A1 (ja) 安定性に優れた固形製剤
CN109010317A (zh) 一种富马酸替诺福韦二吡呋酯颗粒及其制备方法
CN117357481A (zh) 一种口服掩味药物组合物的制备工艺
CN114159397A (zh) 一种磷酸奥司他韦微片及其制备方法和制剂
WO2020080472A1 (ja) コーティング方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20861501

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3146024

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022502045

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022002122

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020343816

Country of ref document: AU

Date of ref document: 20200903

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 112022004080

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022004080

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020861501

Country of ref document: EP

Effective date: 20220404

ENP Entry into the national phase

Ref document number: 112022002122

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220204

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112022004080

Country of ref document: BR

Free format text: PEDIDO RETIRADO COM BASE NO ART. 216, INCISO 2O DA LPI, POIS O DOCUMENTO DE PROCURACAO NAO FOI PROTOCOLADO EM SESSENTA DIAS CONTADOS DA PRATICA DO PRIMEIRO ATO DA PARTE NO PROCESSO E NAO HOUVE INTERPOSICAO DE RECURSO DO REQUERENTE FRENTE A PUBLICACAO DO ARQUIVAMENTO DA PETICAO NA RPI 2682 DE 31/05/2022.